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COMPUTATIONAL MODELING OF SPLICING REGULATION 
 
Alternative splicing is one of the most important post-transcriptional modification in 
cell. It increases the coding capacity of the genome by enable one gene encoding 
multiple proteins. The majority of human protein-coding genes undergo alternative 
splicing. And mis-splicing of those genes are known to be associated with many 
human diseases. Therefore, it is important to study and understand the splicing 
regulatory machinery. The splicing regulation consists of two components: trans-
acting regulators and cis-acting elements. In this dissertation, we explored these 
two aspects of splicing regulation. First, we investigate the relationship of three key 
trans-acting regulators: hnRNP A1, SRSF1 and U2AF with transcriptome-wide 
individual-nucleotide resolution cross-linking and immunoprecipitation (iCLIP) data. 
Our result revealed the competition relationship between hnRNP A1 and SRSF1 
on 3’ splicing sites, and the inhabitation effects on U2AF recruitment after hnRNP 
A1 overexpression. We also discovered that Alu elements may serve as cis-acting 
elements and compete with authentic exons for the binding of U2AF. Second, we 
developed a machine learning algorithm to prioritize the disease-causing 
probability of intronic single-nucleotide variants (iSNVs) by evaluating their cis-
acting impact on both alternative splicing and protein structure. The resulting 
predictive model can predict pathogenic iSNVs with high accuracy and outperform 
popular algorithms such as splicing-based analysis of variants (SPANR) and 
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combined annotation–dependent depletion (CADD). This suggests that protein 
structure features can provide additional layer of information in prioritizing 
pathogenic iSNVs. In conclusion, our studies provide remarkable insights on 
alternative splicing regarding both trans-acting regulation and cis-acting regulation. 
The discoveries of our research on trans-acting regulators are valuable for 
understanding splicing regulatory machinery. The algorithm we developed can be 
used to prioritize pathogenic iSNVs without needing to test them all in expensive 
and laborious assays. 
 
Huanmei Wu, PhD, Chair 
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 Introduction 
1.1 Background 
Alternative splicing is a post-transcriptional process that allows one gene to code 
multiple proteins. Recent high-throughput sequencing studies estimate that more 
than 95% of human multi-exon genes undergo alternative splicing [1]. The 
malfunction of splicing can cause a lot of human diseases. It has been estimated 
that 60% of mutations cause disease by disrupting splicing [2]. Thus, the study of 
splicing regulation is very important. 
 
Splicing regulation consist of two parts. The first part is trans-acting regulations. 
Trans-acting regulation is performed by RNA binding proteins which can bind to 
different regulatory elements and act as splicing repressors or activators. The 
majority of splicing repressors are heterogeneous nuclear ribonucleoproteins 
(hnRNPs) such as hnRNP A1. On the other hand, most of the splicing activators 
are members of the serine/arginine-rich  protein family (SR proteins) such as 
SRSF1 (also known as SF2) [3]. The splicing repressors and activators can inhibit 
or promote the binding of splicing factors such as U2 auxiliary factor (U2AF), assist 
the assembly of spliceosome, and further affect the alternative splicing [4]. 
Investigating of key trans-acting regulators can help us understand the splicing 
machinery. 
 
The second component of splicing regulation is cis-acting elements. Such 
regulatory elements consist of exon and intron splicing enhancers (ESEs and 
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ISEs), as well as silencers (ESSs and ISSs) [3]. Those elements locate at different 
genomic regions can promote or suppress the inclusion of exons. The same 
regulatory element can have different effects on splicing regulation when bound by 
different RNA binding proteins. Hence, the trans-acting regulators and cis-acting 
elements work together as a complex system to regulate the alternative splicing. 
 
The function of cis-acting elements can be disrupted by genetic mutations. Intronic 
regions are a common source of such genetic mutations. Many of the mutations in 
intronic regions affect pre-mRNA splicing. Alternative splicing occurs in the 
majority of genes and frequently alters the function of the resulting gene. Since 
there are a large number of intronic variants but only a small fraction of them cause 
altered biological functions, it is important to be able to predict the impact of the 
variants without needing to test them all in expensive and laborious assays. 
 
In this dissertation, our goal is to: 1.) investigate trans-acting regulatory mechanism 
of several key splicing-related RBPs; and 2.) predict the cis-acting impact of 
intronic variants on splicing outcome and protein function. 
 
1.2 Trans-acting Regulatory Mechanism of RNA Splicing 
1.2.1 Significance 
Trans-acting regulators compose a key component of splicing regulation. While 
there are hundreds of regulators involve in the mRNA splicing, only a small 
proportion of them are well studied. Moreover, the relationship between regulators 
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and how they contribute to the global splicing regulation network need to be 
thoroughly investigated. Regulators like U2AF, hnRNP A1, and SRSF1 interact 
with each other and contribute in the initial process of spliceosome assembly. 
Analysis of their binding patterns with high-throughput sequencing technology in 
the whole transcriptome can help understand their role in splicing regulation 
network.  
 
An Alu element is a kind of DNA repetitive element only exists in primate [5]. With 
over one million copies, it is known to be the most abundant transposable element 
in the human genome [6]. While cumulative evidence suggests it plays a critical 
role in nonsense-mediated mRNA decay and primate evolution, its role in splicing 
regulation remains less understood [7-9].  
 
1.2.2 Critical Barrier 
As mentioned above, the splicing regulation is a very complex system involves 
hundreds of RBPs. Although individual-nucleotide resolution cross-linking and 
immunoprecipitation (iCLIP) and other high-throughput analysis methods allow the 
identification of RBP binding in whole transcriptome scale, large effort is still 
needed to understand the relationship between different RBPs. The same RNA 
binding protein may have different effects on other proteins and alternative splicing 
when binding to different genomic regions. The function of RNA binding proteins 
relate to both genomic context and other RNA binding proteins. Previous low-
throughput studies show the competition relationship between hnRNP A1 and 
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SRSF1 on recruiting splicing factor U2AF. However, transcriptome-wide analysis 
is needed to understand function and relationship of these key splicing regulators. 
 
Although the exonization of Alu is reported to play a role in nonsense-mediated 
mRNA decay, the mechanism of different RBP binding on Alu elements is still 
unclear [10]. The function of Alu in splicing regulation is also unknown. A 
systematically investigation need to be performed to understand the RBP such as 
U2AF binding on Alu elements based on different cellular context. 
 
1.2.3 Innovation 
This study collected the high-throughput sequencing data of hnRNP A1, U2AF and 
SRSF1. Our collaborators constructed hnRNP A1 over expressed cell line, which 
allows us to integrate iCLIP data of hnRNP A1, U2AF and SRSF1 under both 
control and hnRN PA1 over expression conditions. Different RNA binding proteins 
are analyzed as a whole system rather than separated pieces. The relationship 
among those proteins will be analyzed systematically based on different genomic 
context. It can help people to understand the function of those RNA binding 
proteins in alternative splicing regulation.  
 
The U2AF binding change after hnRNP A1 over expression on Alu elements has 
never been reported before. How this binding change affects alternative splicing is 
unknown. The mechanism of how those proteins cooperate or compete around Alu 
elements is also unclear.  This study not only try to interpret the mechanism of 
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U2AF binding change on Alu elements, but also further analyze the effects on 
alternative splicing and nonsense-mediated mRNA decay. 
 
1.3 Cis-acting Impact of Intronic Variants on Splicing and Protein Function 
1.3.1 Significance 
The fundamental goal of genetics is to identify functional variants that can 
potentially cause human diseases. Although the functional importance of intornic 
single nucleotide variants (iSNVs) are not well studied; accumulated evidence 
suggests that iSNVs often affect pre-mRNA splicing and have very important 
phenotypic impacts [11-13]. In the Human Gene Mutation Database (HGMD), 
thousands of SNVs have been documented to be functionally associated with 
human diseases. Among those iSNVs, a large proportion can affect the regulation 
of alternative pre-mRNA splicing [14, 15]. With the current development of high-
throughput genomic technologies, more and more disease-related iSNVs are 
continuing to be identified. 
 
1.3.2 Critical Barrier 
Currently, there are several bioinformatics algorithms that are available to predict 
the functional impact of DNA variants on RNA splicing. However, they lack the 
ability to predict the effect of iSNVs on protein function and further disease 
phenotypes. To effectively study thousands of iSNVs for further functional and 
clinical researches, an effective bioinformatics algorithm is required for prioritizing 
the disease-causing probability of iSNVs based on their impacts on splicing 
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regulation and protein function. So far, there is only one algorithm, SPANR 
(Splicing-based Analysis of Variants), can predict the effect of iSNVs on splicing. 
However, it cannot predict the disease-causing probability and does not consider 
the impact of the alternatively spliced exons on the protein function [16]. Our 
studies on small insertions/deletions (INDELs) and synonymous SNVs suggest 
that simply including or excluding a sequence of amino acids does not necessarily 
alter the protein function [17-19]. This is also confirmed by previous reports that 
splicing-related variations can be “passenger” variants, and thus unimportant to 
the phenotype [20]. Therefore, to predict the functional importance and disease-
causing probability of iSNVs, it is important to integrate the protein structure-
related features that determine the impacts of alternatively spliced exons on 
protein structure and function. 
 
1.3.3 Innovation 
One major challenge of predict the functional importance of iSNVs is the lack of 
training data sets. In this study, we collected a high quality training and testing 
dataset on functional iSNVs by integrating the data from several proprietary and 
public data sources. First, we collaborated with the Human Gene Mutation 
Database (HGMD), and extracted all the iSNVs that are manually curated to cause 
human diseases by altering RNA splicing. The current HGMD professional 
database contains > 3,000 intronic disease-causing iSNVs that affect RNA splicing. 
Additionally, the iSNVs reported in the ClinVar database, a public database that 
contains potential human pathogenic variants, are used as an independent test set 
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[21]. To our knowledge, this is the most comprehensive and high quality dataset 
to study the function impacts of iSNVs in human diseases. 
 
Besides genomic features that potentially disrupt binding affinities of RNA-binding 
proteins (RBP), our predictive algorithm innovatively integrates protein structure 
related features which can characterize the impacts of alternatively spliced exons 
on protein function. As shown in our previous INDEL (insertion/deletion) study, the 
inclusion and exclusion of amino acid sequences does not necessarily alter the 
function of affected proteins. In this study, our result demonstrates that including 
protein structure related features significantly improves prediction power when 
prioritizing pathogenic iSNVs. This represents the major innovation of the 
developed algorithm since the only published algorithm that can be used for iSNVs 
prioritization, SPANR, only predicts how an iSNV can affect splicing outcome and 
does not consider if the affected exon can alter protein function [16].  
 
Finally, the bioinformatics algorithm we developed in this study can effectively 
combines multi-omic datasets form the public domain. This includes data form the 
1,000 Genome Projects, Human Gene Mutation Database, ClinVar, GTEx 
(Genotype-Tissue Expression) project, CLIPdb (CLIP-seq dataset repository), and 
RNAcompete (in vitro RNA binding protein – RNA interaction map) [22-24]. 
Additionally, several of bioinformatics tools that are developed for RNA biology and 
protein structure prediction such as SPINE-D and SPINE-X are also integrated into 
the model [25, 26]. 
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1.4 Objectives 
The main objective of this dissertation is to explore the splicing regulation 
machinery through two aspects. First, we investigated the relationship of three key 
splicing regulators: hnRNP A1, SRSF1, and U2AF. Second, we developed a 
machine learning model to predict the cis-acting impact of intronic single-
nucleotide variants on splicing outcome and protein function. 
 
Chapter 2 reviews the function and importance of RNA splicing, as well as its 
association with diseases. It introduces the two components of splicing regulation: 
trans-acting regulators and cis-acting elements. It also summarizes the 
experimental assays and computational approaches to investigate the trans/cis-
acting splicing regulation. Current algorithms used to predict the functional impacts 
of genetic variants are also discussed in this chapter. 
 
Chapter 3 describes the major findings we got from the iCLIP data on hnRNP A1, 
SRSF1, and U2AF. We investigated the competition relationship between hnRNP 
A1 and SRSF1 in U2AF recruitment in the whole transcriptome. We also 
discovered the absorptive ability of Alu elements on U2AF triggered by hnRNP A1 
overexpression. The iCLIP data in both control and hnRNP A1 overexpression 
HEK293 cell lines are provided by Jonathan Howard and Jeremy Sanford from 
Molecular, Cellular and Developmental Biology Department, University of 
California Santa Cruz.  
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Chapter 4 describes the machine learning model we developed to prioritize the 
disease-causing probability of intronic single-nucleotide variants (iSNVs). We 
evaluated not only the influence of iSNVs on alternative splicing, but also the 
impact of altered exons on protein function. By combining the splicing, 
conservation, and protein structural features, our method can prioritize pathogenic 
iSNVs with high accuracy. 
 
Chapter 5 concludes that our research is valuable for understanding the splicing 
regulation. The predictive model we proposed can pre-screen large scale of 
intronic variants for further experimental validation. This chapter also discusses 
the further direction of our study. 
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 Literature Review 
2.1 Alternative Splicing 
Gene splicing is one of the most important post-transcriptional modification in 
which primary transcript RNA is converted into mature RNA. This modification is 
important for the correct translation of eukaryotic genome since the precursor 
messenger RNA (pre-mRNA) consists of both exons and introns. During the 
splicing process, introns are removed from the pre-mRNA and exons are ligated 
to re-form the mature messenger RNA (mRNA) molecule. The resulting mRNA is 
then further decoded by ribosomes to generate proteins. 
 
The RNA splicing process can generate different mature mRNA molecules from 
the pre-mRNA transcribed from one gene by altering the exon composition of the 
RNA molecule. This is known as alternative splicing. Alternative splicing can 
happen because of different types of splicing events. Exons can be included or 
excluded. Introns can be removed or retained. Exons can also have alternative 3’ 
splice sites (acceptor sites) or 5’ splice sites (donor sites). With numerous 
combination of splicing events, alternative splicing allows one gene to greatly 
increase its coding capacity. Hence, alternative splicing is a critical cause of 
proteomic diversity. 
 
2.1.1 The Function and Importance of Splicing 
Recent researches suggest that human genome may contain as few as 19,000 
protein-coding genes [27]. In contrast, it is estimated that there are above 200,000 
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proteins in human genome [28]. Alternative splicing is one of the major reasons 
why such a large number of proteins can be coded in a much smaller number of 
genes. Current high-throughput sequencing studies show that more than 90% of 
human genes are alternatively spliced [1, 29, 30]. As a result, the coding potential 
of human genes are significantly boosted by alternative splicing. Consequently, 
proteins can have varies functions due to the regulation of alternative splicing. 
 
Alternative splicing has a great potential to regulate the function of proteins by alter 
the exon composition of protein-coding transcripts. A lot of studies show that 
alternative splicing have significant biological effects in different species, despite 
the fraction of alternative splicing has such impact is hard to estimate [31]. 
Although the function change caused by a single splicing event usually is small, 
changes often happen at a bunch of related genes regulated by a small set of 
splicing regulatory proteins, which can have strong biological effects. Such effects 
can include the regulation of the protein-protein interaction, protein-nucleic acid 
interaction and the binding of membrane proteins. Alternative splicing can also 
control the protein localization, enzyme activity as well as their interaction with 
ligands [32]. These impacts suggest that alternative splicing play critical role in the 
physiological process.  
 
2.1.2 The Relationship between Alternative Splicing and Disease 
The functional importance and complexity of alternative splicing make it vulnerable 
to genetic and environmental changes [33]. The malfunction of splicing is known 
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to associate with many human diseases [16, 34]. Studies show that 10% of 
pathological mutations locate at splice sites [35, 36]. Further, it has been estimated 
that 60% of mutations cause disease by disrupting RNA splicing [2, 37]. 
 
Such a huge number of disease-associated alternative splicing events can be 
results of different mechanisms [34, 36]. First, mutations directly happen at splicing 
sites of functional important proteins can cause diseases. Studies show that in 
familial dysautonomia (FD), 99.5% of cases are caused by the intronic mutation 
near 5’-splice site of exon 20 in IKBKAP gene [38]. This mutation can prevent the 
binding of U1 and cause the skipping of exon 20. Such exon skipping can introduce 
the premature stop codon and result in the malfunction of IKBKAP [39]. Second, 
splicing regulatory elements can be affected by pathogenic mutations. Evidence 
show that in spinal muscular atrophy (SMA), the mutation happens at splicing 
regulatory element of exon 7 in SMN2 converts an exonic splicing enhancer (ESE) 
to an exonic splicing silencer (ESS) by allowing a binding site for hnRNPA1 [40, 
41]. This causes the exon skipping of exon 7 in SMN2 and produces nonfunctional 
SMN2 protein [42]. Third, the dysfunction of splicing factors can also disrupt the 
alternative splicing of critical proteins. In frontotemporal lobar degeneration (FTLD) 
and amyotrophic lateral sclerosis (ALS), splicing factor TDP43 is cleaved by 
caspase-3 [43, 44]. Loss of TDP43 expression induces anomalous upregulation of 
CDK6, which causes the cell death in FTLD [45]. 
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Significant number of alternative splicing changes are also found in many cancers. 
Evidence suggests that the changes of splicing regulators such as hnRNPs and 
SR proteins are related to cancer development. For instance, the expression level 
and activity of YB1 and ASF/SF2 have been reported to change in ovarian and 
breast cancer [46, 47]. In addition, several studies demonstrate that splicing 
alterations in cancer-associated genes can be critical in cancer progression. One 
example is that the mutation near the splicing site of exon 2 in tumor suppressor 
KLF6 can induce the expression of KLF6-SV1 isoform. The upregulation of such 
isoform promotes the cell proliferation and results in the acceleration of prostate 
cancer [48-50]. Another example is the mutations at donor site of intron 4 in 
adenomatous polyposis coli (APC) can cause exon skipping and lead to the familial 
adenomatous polyposis (FAP) [51]. All those examples illustrate that the alteration 
of splicing play important role in cancer development and progression. Study of 
splicing regulation is critical in cancer diagnosis and treatment. 
 
2.2 Splicing Regulation 
RNA splicing is regulated by the combination of both trans-acting regulators and 
cis-acting elements. The detail function of those two components will be discussed 
in the following sessions. With the assistance of those two, a series of 
phosphodiester transfer reactions are performed by a large RNA and protein 
complex known as the spliceosome. The spliceosome is composed of more than 
100 proteins and five small nuclear ribonucleoproteins (snRNPs) [4]. There are two 
types of spliceosomes: the major spliceosome which involves in the canonical 
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splicing; and the minor spliceosome which involves in the non-canonical splicing 
[52]. 
 
The major spliceosome, which performs canonical splicing, contains snRNP U1, 
U2, U4, U5, and U6 [4, 53]. During the splicing process, snRNP U1 recognizes 
and binds to the GU sequence at the 5’ splicing site of an intron [54]. Other RNA-
binding proteins such as splicing factor 1 (SF1) binds to the branch site of the intron 
[55]. U2 auxiliary factor 1 and 2 (U2AF1/U2AF2) then binds to the 3' splice site and 
polypyrimidine tract respectively [56]. In this stage, a complex known as E complex 
is assembled. Next, snRNP U2 replaces SF1 and binds to the branch site with 
assistance of U2AF [57]. This forms a pre-spliceosome A complex. Formation of 
A complex is considered playing a critical role in determining the exon-intron 
boundary during alternative splicing [3]. Further, a U4/U6.U5 tri-snRNP is recruited 
with U5 binding to the 5’ splicing site of exon region and U6 binding to snRNP U2 
[58]. The intermediate product is known as pre-catalytic spliceosome B complex. 
It is then converted to B* complex by releasing snRNP U1, shifting U5 from exon 
to intron region, and attaching U6 to 5’ splicing site [59]. Finally, snRNP U4 is 
released and catalytic spliceosome C complex is generated with a series of 
conformation changes. The C complex then performs two transesterification 
reactions. The first one cleaves the 5'-end of the intron and ligates it to the branch 
site to form a lariat through a 2',5'-phosphodiester linkage [60]. The second one 
cleaves 3'-end of the intron, and ligates the two exons together through ATP 
15 
hydrolysis. The lariat is then released and degraded [61]. This whole process is 
known as canonical splicing or lariat pathway. 
 
While canonical splicing explaining more than 99% of splicing, non-canonical 
splicing happens much less frequently [62]. The non-canonical splicing is carried 
out by minor spliceosome which consists of a different set of snRNPs comparing 
to the major spliceosome. The snRNPs U1, U2, U4, and U6 in major spliceosome 
are replaced with U11, U12, U4atac, and U6atac respectively in minor spliceosome 
[63]. The snRNP U5 is shared by both major spliceosome and minor spliceosome. 
Consequently, minor spliceosome recognizes non-canonical splicing site rather 
than the canonical one (GU-AG) [62]. Also, it locates near the nuclear membrane 
outside the nucleus [64]. 
 
2.3 Trans-acting Splicing Factors and Their Role in Splicing Regulation 
Besides the core proteins of spliceosome, splicing relies on the regulation of 
numerous trans-acting regulators. Trans-acting regulators are RNA-binding 
proteins which can promote or suppress the splicing process. Based on their 
function, they can be classified as activators and repressors. However, the function 
of those trans-acting regulators usually depend on the location of binding [65]. By 
binding towards different regions of RNA, a regulator can switch its role between 
activator and repressor. This special phenomenon introduces additional 
complexity into the splicing regulation. Despites such complexity, tremendous 
efforts have been put into the research of key trans-acting regulators such as 
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serine/arginine-rich proteins (SR proteins), heterogeneous nuclear 
ribonucleoprotein (hnRNP), and U2 auxiliary factor (U2AF). 
 
SR proteins constitute a family of proteins which involve in splicing regulation [66]. 
All members of the family contain two protein domains: the RNA recognition motif 
(RRM) region and the RS domain with enriched serine (S) and arginine (R) 
residues [67]. Most studies suggest that SR proteins serve as activators in splicing 
process [68, 69]. During spliceosome assembly, SR proteins bind to the exonic 
splicing enhancers (ESEs) and recruit snRNP U1 and U2AF to the 3’ splicing site 
and 5’ splicing site respectively [70, 71]. This process helps to stabilize the 
formation of E complex. Later, SR proteins also assist snRNP U2 recognizing and 
binding to the branch site, which converts E complex to A complex [72, 73]. Finally, 
SR proteins can recruit U4/U6.U5 tri-snRNP and help to assemble B complex [74, 
75]. As stated above, trans-acting regulators may play as different role when 
binding to different positions. SR proteins serve as activators when binding to 
exonic regions, but act as repressors when binding to intronic regions [70, 76]. 
These mechanisms show that SR proteins play critical roles in both constitutive 
splicing and alternative splicing regulation. 
 
hnRNPs are protein complexes of RBPs and heterogeneous nuclear RNAs 
(hnRNAs). They typically contain at least one of the three RNA-binding motifs: the 
RNP-CS-RBD domains; the RGG (Arg-Gly-Gly) domains; and the K-homology (KH) 
domains [77]. Although the mechanism of how hnRNPs regulate splicing is unclear, 
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they are most known as repressors in splicing regulation [78]. Reports show 
hnRNPs can compete with SR proteins and suppress the exon inclusion. During 
this process, hnRNPs may bind to the exonic splicing silencers (ESS) and prevent 
the binding of SR proteins to the adjacent ESE [79, 80]. On the other hand, similar 
to SR proteins, hnRNPs can also perform as splicing activators. Studies show that 
hnRNPs can help recruit U2AF to assemble spliceosome by proofreading 3’ 
splicing site AG dinucleotides [81]. 
 
U2 auxiliary factor (U2AF) is a heterodimer which consists of two subunits: 
U2AF65 (65-kDa) and U2AF35 (35-kDa) [82, 83]. U2AF65 contains four RNA-
binding domain and binds to the pyrimidine tract (Py tract) upstream of 3’ splicing 
sites, while U2AF35 associates with the AG dinucleotide at 3’ splicing sites [84-
87]. Binding of U2AF is required for the recruitment of snRNP U2 and the assembly 
of spliceosome [88]. Multiple studies show that U2AF can help recognize and 
define 3’ splicing sites, as well as regulate alternative splicing [89-91]. At the 
meantime, the binding of U2AF is also regulated by other RNA-binding proteins 
including hnRNPs and SR proteins. It has been shown that U2AF has direct 
competition relationship with certain hnRNPs such as hnRNP C [10]. Contrarily, 
the binding of SR proteins can help recruit U2AF during spliceosome assembly 
[70]. 
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2.4 Technologies for Detecting RNA-protein Interaction 
Since RBPs play critical roles in RNA splicing, investigating RNA-protein 
interaction can help to understand the mechanism of splicing regulation and 
determine the effects of RBPs on the transcriptome. Due to the importance and 
complexity of RBPs, several methods have been developed to study the interaction 
between RNA and proteins. Traditionally, such interactions were analyzed in a low-
throughput manner. In recent years, high-throughput techniques such as 
microarray and high-throughput sequencing allow researchers to investigate the 
function of RBPs systematically. 
 
Systematic evolution of ligands by exponential enrichment (SELEX) is an effective 
approach to identify the binding motifs of RBPs [92]. The process first synthesizes 
all the possible short oligonucleotides randomly as potential targets. The random 
oligonucleotides are then exposed to interested RBPs. After washing away un-
bound oligonucleotides, the bound targets are amplified with RT-PCR [93]. This 
method is wildly used to determine high affinity RBP binding motifs. However, 
SELEX usually can only detect motifs with the highest affinity and fail in identifying 
moderate and low affinity motifs [94, 95]. Moreover, traditional SELEX analysis 
lacks the ability to investigate the RBP binding sites across the whole 
transcriptome in vivo. 
 
To systematically investigate the RNA-protein binding within a cellular context, 
RNP immunoprecipitation (RIP) followed by microarray (RIP-Chip) or high-
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throughput sequencing (RIP-Seq) is developed [96, 97]. The main process relies 
on immunoprecipitation of RBPs with specific antibodies. Any RNA fragments that 
bound by the RBP of interest pulled down. The isolated RNAs then can be 
analyzed with microarray or high-throughput sequencing technology [98]. This 
method allows the measure of dynamic RBP binding status. It can not only capture 
the RNA-protein interaction but also keep the information of RNA-RNA interaction 
[99].  However, this approach can only be used on ribonucleoprotein particles 
(RNPs) and the low resolution of the data limits the accuracy of RBP binding sites 
identification [100, 101]. 
 
In order to address the drawbacks of RIP, cross-linking immunoprecipitation (CLIP) 
is developed to investigate the RNA-protein interaction with high resolution and 
specificity [102-104]. This approach utilizes ultraviolet (UV) light to cross-link RNA 
and proteins in vivo. The UV light will induce the formation of covalent bonds 
between proteins and nucleic acids, which can stabilize the RNA-protein complex 
[105]. After isolating the RNA-protein complex with antibodies, the protein will be 
digested with Proteinase K. The remaining RNA molecules can be enriched with 
RT-PCR for further analysis [102]. Originally, the downstream analysis is 
performed by Sanger sequencing. After the invention of high-throughput 
sequencing, several modified approaches are developed to improve the scale and 
accuracy of detection. 
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High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
(HITS-CLIP), also known as CLIP-Seq, combines CLIP with high-throughput 
sequencing technology to detect RNA-protein interaction across the whole 
transcriptome [106]. Since the UV cross-linking is irreversible, the peptides are left 
at the cross-link sites after Proteinase K digestion. These peptides can affect 
reverse transcriptase during RT-PCR step and produce truncated cDNA molecules. 
Even if the reverse transcriptase can read through those cross-link sites, higher 
error rate will be induced during nucleotide base paring [102]. Such cross-linking 
induced mutation sites (CIMS) can provide additional information for identifying 
RNA-protein binding sites with high resolution [104]. 
 
Photoactivatable ribonucleoside–enhanced crosslinking and immunoprecipitation 
(PAR-CLIP) is developed to increase the resolution of detecting RNA-protein 
interaction. Due to the low efficiency of 254 nm UV used in the HITS-CLIP and the 
low percentage of CIMS in read-through cDNA fragments, the ability of identifying 
exact RNA-protein binding sites is limited [107]. PAR-CLIP solves this issue by 
adding photoreactive ribonucleoside analogs into the RNA of cultured cells. 365 
nm UV light is then used to cross link the photoreactive ribonucleoside-labeled 
transcripts with RNA-binding proteins. Introducing of photoreactive ribonucleoside 
analogs, such as 4-thiouridine (4-SU) and 6-thioguanosine (6-SG), can cause 
thymidine to cytidine, and guanosine to adenosine mutations during cross-linking 
process respectively [108]. Such process can effectively produce CIMS for high-
resolution RNA-protein binding site detection. However, PAR-CLIP can only be 
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applied on cultured cells, which limits its application on tissue-based assays [101]. 
Also, studies show that the incorporation ribonucleoside analogs may inhibit the 
synthesis of ribosomal RNA and trigger a nucleolar stress response [109]. 
 
Individual-nucleotide resolution cross-linking and immunoprecipitation (iCLIP) 
allows the identification of RBP binding sites at single nucleotide resolution. It 
improves HITS-CLIP with cDNA circularization after reverse transcription. This 
modification enables both truncated and read-through cDNAs to be sequenced 
effectively [110]. Mapping of truncated sites back to genome can allow 
identification of cross-link sites at nucleotide level [111]. 
 
2.5 Cis-acting Elements and Their Influence on Splicing Regulation 
Splicing regulatory elements (SREs) are short cis-acting regulatory sequences 
locate in transcripts. They can recruit trans-acting regulators to promote or inhibit 
the splicing process. Based on the function and location of those elements, they 
can be classified as exonic splicing enhancers (ESEs), exonic splicing silencers 
(ESSs), intronic splicing enhancers (ISEs), and intronic splicing silencers (ISSs) 
[4].  
 
Splicing Enhancers are usually bound by activators such as SR proteins. SR 
proteins which bind to ESEs through their RRM domains can further recruit 
U2AF65 with RS domains for spliceosome assembly [112]. ESEs can also promote 
splicing through bridging interactions with the help of SRm160 and SRm300 [113, 
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114]. During this process, those splicing co-activators can mediate the interactions 
between SR proteins and snRNPs. In addition, ESEs can assist the binding 
between RS domains and branch sites, which may promote the formation of A 
complex [72, 115]. ISEs activate splicing through different mechanisms. One 
example is that the binding of hnRNP L to the CA repeats can recruit snRNP U1 
to weak 5' splice sites [116].  
 
Splicing Silencers typically interact with repressors such as hnRNPs. They inhibit 
splicing through two mechanisms [3]. First, silencers can block the access of 
activators to the splicing sites by recruiting high-affinity repressors. Polypyrimidine 
tract-binding protein (PTB), as a member of hnRNP family, can bind to ESSs and 
compete with U2AF65 [117]. This process can prevent the interaction between 
snRNP U1 and U2, which inhibits the assembly of A complex [118]. Second, 
splicing silencers can bind to either side of exons and loop out the exon in between, 
suppressing the splicing reaction. The binding of hnRNP A1 to ESSs can block the 
recruitment of snRNPs and SR proteins, which can induce the “looping out” of exon 
[79, 119]. Similarly, ISSs can also be bound by hnRNPs such as PTB, hnRNP A1 
and hnRNP L to inhibit the splicing process [116, 120]. 
 
The function of SREs can also depend on the context. Elements with similar 
nucleotide sequences can function as enhancers or silencers based on the relative 
positions within transcripts [121]. For instance, poly-G usually serve as splicing 
enhancers when located in intronic regions, but they can suppress the splicing 
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when located in exonic regions [122, 123]. In contrast, the YCAY binding motifs of 
neuro-oncological ventral antigen (NOVA) act as splicing enhancers or silencers 
when located in exons or introns, respectively [124]. Such “context dependence” 
of SREs exhibits the flexibility and complexity of splicing regulation.  
 
2.6 Methods for Modeling Cis-acting Splicing Regulation 
With the utilization of high-throughput sequencing in RNA-protein interaction 
studies, a large number of cis-acting elements and associated trans-acting 
regulators are identified. It dramatically extends our knowledgebase on splicing 
regulation. Numerous attempts have been made to predict the splicing pattern 
based on known regulatory elements and splicing machinery. 
 
ExonScan achieves this goal by simulating the splicing process based on cis-
acting regulatory elements located in transcripts [125]. The algorithm scans the 
pre-mRNA and looks for potential splicing sites with maximum entropy splice site 
models [126]. A score is then assigned to each candidate exon based on 
enrichment of regulatory elements in the nearby region. Enhancers and silencers 
contribute to positive and negative scores respectively. The score cutoff is trained 
based on a set of 1,820 human genes to achieve high accuracy. The results give 
the prediction of splicing outcome of given primary transcripts. 
 
Algorithm like ExonScan, however, does not take into account the tissue specificity 
of alternative splicing. The splicing outcome is co-regulated by both cis-acting 
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elements and trans-acting regulators, while the expression and activity of trans-
acting regulators is tissue-dependent. Yoseph et al. addressed this issue by 
combining hundreds of RNA features to predict tissue-specific alternative splicing 
changes [127]. They collected both the genomic features around exons of interest 
and splicing profiles across different tissue types. A splicing code was inferred with 
selected features to predict the splicing pattern in particular tissue types using 
information theory [128]. This method can be used to predict alternative splicing in 
a tissue-specific manner. And the result of the prediction can be evaluated to help 
better understand the splicing regulation machinery. 
 
Michael et al. further improved such prediction framework by adopting deep 
learning architecture [129]. They extended the feature set to over a thousand RNA 
features. Those features, together with the tissue-specific splicing profiles, were 
used to build a multi-layer deep neural network [130]. Such model can predict not 
only the absolute percentage of spliced in (PSI) of exons for each tissue types, but 
also the splicing change (delta PSI) between different tissues. The result 
demonstrates the regulatory function of both cis-acting elements and trans-acting 
regulators. The various model performance across different tissues, however, 
suggests the complexity of splicing regulation.  
 
2.7 Algorithms for Prioritizing Functional Effect of Variants 
Single nucleotide polymorphisms (SNPs) are the most common genetic variants 
in the human genome, and they are believed to involve in many diseases. Much 
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effort has been put into the prediction of functional effects of SNPs. Most early 
algorithms focus on exonic non-synonymous SNPs (nsSNPs) due to their 
simplicity and data availability. Two of the most widely used algorithms are SIFT 
and PolyPhen-2 [131]. SIFT predicts the impacts of nsSNPs on protein function 
based on sequence homology information gathered by PSI-BLAST, as well as the 
physical properties of amino acids [132].  PolyPhen-2 collects not only sequence 
and phylogenetic related information but also structure-based features. A naive 
Bayes classifier is then trained to predict the functional effects of SNPs [133]. 
 
As increasing number of prediction algorithms being developed, researchers 
realized the limitation of using single predictive method. Ensemble learning 
framework like combined annotation–dependent depletion (CADD) has been 
developed to overcome such limitation [134]. CADD integrated the genomic 
features such as GERP, phastCons, phyloP, as well as prediction scores from 
other algorithms like SIFT and PolyPhen-2. It then built a support vector machine 
(SVM) on top of those to predict the deleteriousness of SNPs. Although the 
prediction power is improved by such method, the performance is still restrained 
by the individual model and features used in each sub-models. 
 
Since the price of whole-genome sequencing drops below $1,000, more and more 
intronic SNPs data are available. Intronic SNPs started to gather its attention on 
functional prediction. Most of tools focus on predicting the impacts of intronic SNPs 
on splicing outcome. SPANR is based on a neural network trained on RNA-Seq 
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data of 16 tissue types with more than a thousand genomic features [16]. It can 
predict the delta percentage of inclusion (dPSI) of exons caused by nearby intronic 
SNPs. However, such method fail to consider how those altered exons will affect 
the function of transcribed protein products. Our previous studies on small 
insertions/deletions (INDELs) and synonymous SNVs demonstrate that simply 
altering the inclusion of an exon may not have any impact on protein function [17]. 
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 Alu Elements and hnRNPA1 Facilitate Transcriptome-wide 
Redistribution of Splicing Factor U2AF2 
3.1 Introduction 
Alternative splicing drives transcriptome and proteome diversification. While 
splicing regulatory proteins govern this process, their global mechanisms remain 
enigmatic. Splicing factors orchestrate the assembly of alternative messenger 
RNA transcripts from precursor mRNA. This process diversifies genetic 
information by expanding the coding capacity of the genome [121]. hnRNPA1 is a 
splicing silencer that is overexpressed in many human cancers [135-139]. 
Biochemical experiments suggest hnRNPA1 regulates exon inclusion through 
several mechanisms [79, 80, 140-144]. One commonality may be antagonization 
of splicing factors that recognize the 3' splices site. hnRNPA1 modulates 
interactions between U2AF2 and the polypyrimidine track [81]. Likewise, 
hnRNPA1 may also influence the association of SRSF1 with exonic splicing 
enhancer sequences [79, 140] (Figure 1). Despite recent genome wide protein-
RNA interaction studies the generality of these models remains enigmatic [145-
147]. Our collaborator generated high resolution transcriptome-wide protein-RNA 
interaction maps to determine how the splicing repressor hnRNPA1 influences the 
global association of spliceosome assembly factor U2AF2 and SRSF1 with pre-
mRNA. We observed changes in the distribution of U2AF2 crosslinking sites 
relative to the 3’ splice sites of cassette exons but not constitutive exons upon 
hnRNPA1 overexpression. By contrast, SRSF1 crosslinking patterns relative to 
splice sites are independent of hnRNPA1 expression levels. We also observed an 
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hnRNPA1-dependent increase in U2AF2 but not SRSF1 crosslinking to exon 
proximal antisense Alu elements. Thus Alu elements can serve as splicing factor-
responsive sinks for U2AF2. These results not only demonstrate a novel 
mechanism for alternative splicing regulation but also implicate retrotransposon-
derived sequences in the evolution of species-specific alternative splicing. 
 
All the PCR, sequencing, and western blot experiment are performed by Jonathan 
Howard and Jeremy Sanford from Molecular, Cellular and Developmental Biology 
Department, University of California Santa Cruz. 
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Figure 1 hnRNPA1 regulatory mechanisms. Potential models by which hnRNPA1 
is thought to regulate binding of additional splicing factors to promote exon 
skipping. These models universally suggest hnRNPA1 act primarily as an 
antagonizer of splicing enhancers through different, but not necessarily mutually 
exclusive, mechanisms. 
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3.2 Materials and Methods 
3.2.1 iCLIP method 
iCLIP was performed as previously described [111, 148]. Briefly, TREX FLP-in 
HEK293T cells (Invitrogen) lacking or containing a stable, inducible T7-tagged 
version of hnRNP A1. Cells were treated with tetracyclin for 24 hr and then 
irradiated with UV-C light to form irreversible covalent cross-link between proteins 
and nucleic acids in vivo. After cell lysis, RNA was partially fragmented using low 
concentrations of Micrococcal nuclease, and U2AF65-, SRSF1-, or hnRNP A1–
RNA complexes were immunopurified with α-U2AF65, (MC3;SCBT), α-SRSF1 
(96;SCBT), and α-hnRNP A1 (4B10;SCBT) antibodies immobilized on protein A–
coated magnetic beads (Life Technologies), respectively. After stringent washing 
and dephosphorylation (Fast AP, Fermentas), RNAs were ligated at their 3′ ends 
with a pre-adenylated RNA adaptor (Bioo Scientific) and radioactively labeled to 
allow visualization. Samples were run using MOPS-based protein gel 
electrophoresis (in-house recipe) and transferred to a nitrocellulose membrane. 
Protein-RNA complexes migrating 15 -80 kDa above free protein were cut from the 
membrane, and RNA was recovered from the membrane by proteinase K digestion 
under denaturing (3.5 M Urea) conditions. The oligonucleotides for reverse 
transcription contained two inversely oriented adaptor regions adapted from the 
Bioo NEXTflex small RNA library preparation kit (Bioo Scientific), separated by a 
BamHI restriction site as well as a barcode region at their 5′ end containing a 4-nt 
experiment-specific barcode within a 5-nt random barcode to mark individual cDNA 
molecules. cDNA molecules were size-purified using denaturing PAGE gel 
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electrophoresis, circularized by CircLigase II (Epicenter), annealed to an 
oligonucleotide complementary to the restriction site and cut using BamHI (NEB). 
Linearized cDNAs were then PCR-amplified using (Immomix PCR Master Mix, 
Bioline) with primers (Bioo) complementary to the adaptor regions and were 
subjected to high-throughput sequencing using Illumina HiSeq. A more detailed 
description of the iCLIP protocol has been published [111]. 
 
3.2.2 Mapping and Analysis of iCLIP sequencing data 
Single end reads generated by Illumina HiSeq were inspected for the presence of 
adaptor sequences. Reads containing sequences corresponding to the 3’RNA 
adaptor were retained if they were at least 30bp long after the adaptor sequence 
was trimmed off. The first 9bp in each read from the iCLIP library preparation, 
containing an internal barcode comprising 4bp for replicate identification and 5bp 
of random nucleotides for use in duplicate mapping removal, were also removed 
before mapping. Trimmed reads were checked for mapping to a repeat filter 
comprising RepeatMasker elements in the human genome using Bowtie2 [149]. 
Reads that passed the repeat filter were mapped to the transcriptome and genome 
with Tophat [150]. If reads mapped equally well to multiple loci, a single mapping 
was selected randomly by Tophat. Duplicate mappings from each replicate were 
reduced to one per position if they had the same genomic end points and if they 
originated from reads with the same set of random 5bp nucleotides. Following 
mapping and duplicate removal, individual reads were truncated to their 5’ ends to 
represent the site of crosslinking consistent with the iCLIP methodology. For all 
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samples only such crosslinking sites found to have non-zero mapping counts in 
two out of three replicates (or two out of two duplicates where applicable) were 
considered to be biologically reproducible candidates for further analysis. The 
counts at such reproducible crosslinking sites were summed over all replicates to 
create an aggregated data set for each cell condition and CLIP. To determine 
background from the iCLIP data sets, the two cell conditions (control and 
hnRNPA1-overexpressing) were temporarily further aggregated for each CLIP 
(U2AF, SF2, A1) and those binding sites that had non-zero counts in all three 
temporary aggregate data sets were determined.  A 41 nucleotide mask was 
created by extending 20nt upstream and 20nt downstream from each such 3-way 
common binding site. The aggregated data set of binding sites for each cell 
condition and CLIP was then filtered using this mask, keeping only sites outside 
the mask that also had a mapping count of at least 3 in the aggregate data. These 
aggregated and filtered data were used for downstream analyses. This 
aggregation and filtering strategy was adapted from previously described iCLIP 
analysis pipelines [151, 152]. For use as input to CLIPPER [153], the filtered 
(single nucleotide) binding sites were expanded by 15nt upstream and 15nt 
downstream. 
 
CLIPper (CLIP-seq peak enrichment; https://github.com/YeoLab/clipper), was 
used to determine genomic distribution of RNA crosslinking peaks as well as 
identify clusters representing binding sites for hnRNP A1, U2AF2, and SRSF1 for 
each condition as previously described [153]. 
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3.2.3 RBP Binding Analysis 
40,769 cassette exons are extracted from MISO human genome (hg19) alternative 
events annotation version 2. 200,880 constitutive exons are extracted from RefSeq 
gene annotation by excluding the exons that overlap with cassette exons. Gene 
differential expression analysis is done by edgeR. 40,952 constitutive exons that 
are not significantly differential expressed (FDR > 0.05) are used in further analysis. 
For each RNA binding protein in each cell line, the iCLIP reads of all the replicates 
are merged together. The start position of reads are considered as crosslinking 
sites. The number of reads near 3’ splice site (100bp into the intron, 50bp into the 
exon) of each exon is calculated based on a 10bp window. The raw read counts is 
normalized by the total library size. Exons with more than 20 reads in the 150bp 
region are shown in the plot. 
 
The binding changes of U2AF and SF2 near 3’ splice sites are further analyzed 
with edgeR. Read counts are calculated for 200bp intron regions near 3’ splice 
sites of cassette exons. For each RBP, the regions with more than one count per 
million (CPM) in at least half of the replicates in either of the cell line are used for 
binding change analysis. 
 
3.2.4 Relationship between U2AF Binding and Splicing Change 
Among 267 splicing changed skipped exon events, with U2AF binding, the PSI 
(Percent Spliced In) of 74 events are decreased after hnRNPA1 over expression, 
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and the PSI of 9 events are increased. On the other hand, without U2AF binding, 
the PSI of 134 events are decreased and the PSI of 50 events are increased. 
 
3.2.5 Motif Analysis 
For each condition, the iCLIP data of replicates are merged. Binding peaks are 
called with CLIPper. The peaks are divided into different categories based on 
genomic regions including CDS, intron and UTR. Each category is further divided 
based on whether overlap with Alu elements. 50bp sequences of peak region 
(crosslinking site ± 25bp) are extracted. A strand-specific MEME-ChIP analysis is 
performed to find the enriched motifs with width between 6bp to 10bp. 
 
3.2.6 RBP Binding Near Alu Elements 
315,974 anti-sense Alu elements are extracted from RepeatMasker. The merged 
iCLIP data for each condition is down-sampled to 1M reads. The total number of 
sense strand reads are calculated for Alu and nearby regions (250bp from Alu 
boundary). For each cassette exon events (cassette exon + up/downstream 
introns + up/downstream exons), the number of reads in anti-sense Alu elements 
and the total number of reads in the whole event are calculated separately. The 
proportion of reads fall into anti-sense Alu elements for each event is used to 
represent the RBP binding change in Alu regions. 
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3.2.7 mRNA-Seq of Control or hnRNPA1 Over Expressing HEK293 cells 
RNA was isolated from whole cell lysates of control and hnRNPA1-overexpressing 
TREX Flp-IN HEK 293T cells using TRI-Reagent LS (Sigma). Poly-A+ sequencing 
libraries were prepared using the TrueSeq RNA library prep kit (Illumina, San 
Diego, CA). We analyzed each condition in duplicate using the HiSeq2000. 
 
3.2.8 Quantification of Alternative Splicing by RNA-Seq 
Poly-A+ transcriptome sequencing reads were mapped to human reference 
genome (hg19) with TopHat2. Mapped reads of duplicates were merged together 
for splicing analysis. Splicing change was analyzed with MISO [154]. The MISO 
result was filtered with parameters: --num-inc 1 --num-exc 1 --num-sum-exc 10 --
delta-psi 0.20 --bayes-factor 10. After filtering, 267 skipped exon events were left 
for further analysis. 
 
3.3 Results 
3.3.1 hnRNPA1 Overexpression Induces Genome-wide Redistribution of 
SRSF1 and U2AF2 
To determine how hnRNPA1 influences 3' splice site recognition genome-wide, we 
perturbed its expression in HEK293 cells and assayed SRSF1, U2AF2 and 
hnRNPA1 protein-RNA interactions using individual nucleotide resolution 
crosslinking immunopreciptitation and high throughput sequencing (iCLIP-seq) 
[148]. Induction of hnRNPA1 results in an approximately 2-3 fold increase 
compared to the endogenous protein (and relative to EWSR1) and has no 
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appreciable effect on SRSF1 or U2AF2 steady state protein levels (Figure 2). 
Additionally, the expression and localization of hnRNPC are unaffected by 
hnRNPA1 overexpression. We used iCLIP to purify hnRNPA1-, SRSF1-, and 
U2AF2-RNA complexes, from control and hnRNPA1 over-expressing cells (Figure 
4). As expected, the immunoprecipitated material was both UV- and antibody-
dependent, nuclease sensitive and produced robust sequencing libraries (Table 1, 
Table 2, Table 3 and Figure 3). After identification of peaks using CLIPper [153] 
(Table 4) the distribution of hnRNPA1 peaks between different gene regions is 
largely unchanged upon hnRNPA1 overexpression overexpression (Figure 5). 
However, we observed differences between control and hnRNPA1 overexpression 
cell lines for both U2AF2 and SRSF1 peaks (Figure 5). Most notably, the proportion 
of U2AF2 peaks located near coding exons or in exon-proximal intronic regions 
was reduced whereas intronic peaks located more than 500 nt from exons (distal 
intron) increased. A similar trend was observed for SRSF1 peaks, where a 
reduction in CDS and concomitant increase in distal intron peaks was evident upon 
hnRNPA1 overexpression (Figure 5). To determine if hnRNPA1 influences the 
RNA binding specificity of U2AF2 and SRSF1 we searched for over represented 
RNA sequences within the binding site peaks (Figure 6). In control cells, U2AF2 
peaks are characterized by a pyrimidine-AG motif, closely resembling authentic 
3’splice sites. By contrast, a more pyrimidine-rich motif lacking the AG dinucleotide 
is observed in peaks from hnRNPA1 overexpression cells.   By contrast, SRSF1 
and hnRNPA1 motifs are similar between control and hnRNPA1 overexpression 
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cells. These data suggest that enforced expression of hnRNPA1 alters U2AF2 
RNA binding specificity. 
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Figure 2 Western blot analysis of control and hnRNPA1 overexpression cell lines. 
Nuclear extracts were subjected to SDS-PAGE and transferred to nitrocellulose 
blotting paper. Samples were interrogated with anitbodies for α-T7 peptide tag 
(with which overexpressed hnRNPA1 has been tagged), α-hnRNPA1 (4B10; Santa 
Cruz Biotechnology), α-SRSF1 (96;Santa Cruz Biotechnology), α-U2AF2 
(MC3;Santa Cruz Biotechnology), and α-EWSR1 (C-9; Santa Cruz Biotechnology) 
as positive control. 
 
Experiment is performed by Jonathan Howard from Molecular, Cellular and 
Developmental Biology Department, University of California Santa Cruz. 
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Figure 3 Average Duplication Rates of iCLIP replicate libraries. Dot plot showing 
the PCR duplication rate for each sequencing library replicate for each iCLIP 
experiment. “Control” refers to control HEK293 cell lines and “OverExpr” refers to 
cell lines in which hnRNP A1 overexpression has been induced. 
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Figure 4 Examples of iCLIP autoradiographs for each protein under control and 
overexpression of hnRNPA1.  Protein-RNA complex shifts are UV-, antibody- and 
Micrococcal nuclease-sensitive. Bars denote region of nitrocellulose blot excised 
for RNA isolation for iCLIP library preparation. 
 
Experiment is performed by Jonathan Howard from Molecular, Cellular and 
Developmental Biology Department, University of California Santa Cruz. 
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Figure 5 Peak distribution across the genome. CLIPper analysis of iCLIP RNA 
distribution for hnRNPA1, SRSF1, and U2AF2 for control and hnRNPA1 
overexpression conditions. 
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Figure 6 Top HOMER consensus binding motifs for hnRNPA1, SRSF1, and 
U2AF2 for control and hnRNPA1 overexpression conditions.  
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Table 1 iCLIP mapping statistics.  
Sample 
Total 
count 
Mapped 
count 
Mapped 
percentage 
Unique 
count 
Unique 
percentage 
hektrx_hna1_jh103b 28.55M 27.59M 96.60% 25.77M 93.40% 
hektrx_hna1_jh103c 24.43M 23.60M 96.60% 21.98M 93.10% 
hekha1_hna1_jh104a 8.27M 7.91M 95.70% 7.35M 92.80% 
hekha1_hna1_jh104b 9.10M 8.74M 96.00% 8.08M 92.50% 
hektrx_u2af_jh105a 12.54M 11.75M 93.70% 11.03M 93.90% 
hektrx_u2af_jh105b 12.24M 11.79M 96.30% 11.08M 94.00% 
hektrx_u2af_jh105c 17.38M 16.40M 94.40% 15.38M 93.70% 
hekha1_u2af_jh106a 28.23M 25.68M 91.00% 21.18M 82.50% 
hekha1_u2af_jh106b 30.72M 28.12M 91.50% 24.01M 85.40% 
hekha1_u2af_jh106c 37.20M 33.33M 89.60% 27.73M 83.20% 
hektrx_sf2x_jh107a 3.20M 3.04M 95.10% 2.70M 88.80% 
hektrx_sf2x_jh107b 2.63M 2.47M 94.10% 2.16M 87.30% 
hektrx_sf2x_jh107c 2.95M 2.85M 96.50% 2.55M 89.30% 
hekha1_sf2x_jh108a 3.71M 3.56M 96.10% 3.25M 91.30% 
hekha1_sf2x_jh108b 6.09M 5.90M 96.90% 5.45M 92.40% 
hekha1_sf2x_jh108c 5.18M 5.01M 96.80% 4.61M 91.90% 
hektrx_sf2x_jh107a 17.61M 16.78M 95.30% 14.63M 87.10% 
hektrx_sf2x_jh107b 13.06M 12.36M 94.60% 10.44M 84.50% 
hektrx_sf2x_jh107c 13.55M 13.12M 96.80% 11.53M 87.90% 
hekha1_sf2x_jh108a 20.95M 20.14M 96.10% 18.31M 90.90% 
hekha1_sf2x_jh108b 34.03M 33.00M 97.00% 30.44M 92.20% 
hekha1_sf2x_jh108c 26.69M 25.87M 96.90% 23.72M 91.70% 
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Table 2 Comparison of library complexity before and after PCR duplication 
removal using random indexes. A: before PCR duplication removal. B: after PCR 
duplication removal. 
Sample 
Mapped 
count A 
Mapped 
count B 
Ratio 
AB 
hektrx_hna1_jh103b 27.59M 23.25M 1.19 
hektrx_hna1_jh103c 23.60M 19.70M 1.2 
hekha1_hna1_jh104a 7.91M 6.28M 1.26 
hekha1_hna1_jh104b 8.74M 6.91M 1.26 
hektrx_u2af_jh105a 11.75M 10.16M 1.16 
hektrx_u2af_jh105b 11.79M 10.15M 1.16 
hektrx_u2af_jh105c 16.40M 14.02M 1.17 
hekha1_u2af_jh106a 25.68M 8.64M 2.97 
hekha1_u2af_jh106b 28.12M 8.80M 3.2 
hekha1_u2af_jh106c 33.33M 10.60M 3.14 
hektrx_sf2x_jh107a 3.04M 2.36M 1.29 
hektrx_sf2x_jh107b 2.47M 1.82M 1.36 
hektrx_sf2x_jh107c 2.85M 2.14M 1.33 
hekha1_sf2x_jh108a 3.56M 3.04M 1.17 
hekha1_sf2x_jh108b 5.90M 4.99M 1.18 
hekha1_sf2x_jh108c 5.01M 4.21M 1.19 
hektrx_sf2x_jh107a 16.78M 3.88M 4.32 
hektrx_sf2x_jh107b 12.36M 2.57M 4.81 
hektrx_sf2x_jh107c 13.12M 3.02M 4.34 
hekha1_sf2x_jh108a 20.14M 14.64M 1.38 
hekha1_sf2x_jh108b 33.00M 23.86M 1.38 
hekha1_sf2x_jh108c 25.87M 18.74M 1.38 
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Table 3  Summary of aggregated crosslink data from replicate iCLIP experiments.  
 
SRSF1 
CTL 
SRSF1 
CTL 
hnRNPA1 
OE 
hnRNPA1 
CTL 
U2AF 
OE 
U2AF 
CTL 
Total 
coverage 29.45M 3.99M 1.65M 9.82M 16.54M 6.84M 
CDS 
coverage 3.11M 0.34M 0.02M 0.12M 0.42M 0.25M 
CDS 
percentage 10.57% 8.54% 0.97% 1.25% 2.51% 3.63% 
UTR3 
coverage 3.76M 0.66M 0.13M 1.01M 3.70M 0.68M 
UTR3 
percentage 12.78% 16.50% 7.61% 10.30% 22.37% 10.00% 
UTR5 
coverage 0.60M 0.10M 0.02M 0.11M 0.43M 0.11M 
UTR5 
percentage 2.05% 2.55% 0.98% 1.11% 2.57% 1.67% 
Non-
coding 
coverage 4.53M 0.93M 0.25M 0.96M 1.60M 0.99M 
Non-
coding 
percentage 15.38% 23.39% 15.02% 9.80% 9.67% 14.44% 
Exon 
coverage 12.01M 2.03M 0.41M 2.21M 6.14M 2.03M 
Exon 
percentage 40.78% 50.98% 24.58% 22.46% 37.13% 29.73% 
Intron 
coverage 13.59M 1.18M 1.07M 6.36M 5.28M 4.15M 
Intron 
percentage 46.16% 29.52% 64.96% 64.73% 31.93% 60.65% 
Intergenic 
coverage 3.84M 0.78M 0.17M 1.26M 5.12M 0.66M 
Intergenic 
percentage 13.06% 19.51% 10.46% 12.81% 30.94% 9.63% 
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Table 4 CLIPper output statistics from "pre-mRNA" analysis for aggregated iCLIP 
data.  
 
SRSF1 
OE 
SRSF1 
CTL 
hnRNPA
1 OE 
hnRNPA1 
CTL U2AF OE 
U2AF 
CTL 
Mapped 
reads 19.29M 2.41M 0.68M 4.73M 12.92M 2.60M 
Number 
of 
peaks 
          
202,511  
          
22,393  
             
5,789  
            
59,778  
          
125,588  
          
23,918  
Median 
tags 22 23 19 20 26 20 
Averag
e tags 37.1 39.6 26.1 27.6 54.3 29.5 
Median 
length 29bp 34bp 33bp 35bp 14bp 35bp 
Averag
e length 28bp 32bp 29bp 33bp 20bp 33bp 
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3.3.2 hnRNPA1 Influences Binding of SRSF1 and U2AF2 Near 3’ Splice 
Sites 
Previous work demonstrated that hnRNPA1 influences binding of SRSF1 and 
U2AF2 near 3’ splice sites [81, 155, 156]. To test this hypothesis, we determined 
how titration of hnRNPA1 affected the distribution of SRSF1- and U2AF2-RNA 
crosslinks relative to 3’ splice sites of constitutive or alternative cassette exons.  As 
suggested by the peak analysis (Figure 5) there are no differences in hnRNPA1 
crosslinking site between control and overexpression cells (Figure 7 and Figure 8 
left panels, blue and red lines respectively). SRSF1 crosslinking to exonic 
sequences was modestly reduced in the hnRNPA1 overexpression cells compared 
to control, but the positional distribution of the SRSF1 sites relative to the 3’ss was 
largely unchanged for constitutive and skipped exons (Figure 7 and Figure 8, right 
panels). U2AF2 crosslinking distribution relative to the 3’ss was substantially 
altered in hnRNPA1 over expressing cells compared to the control, where a 
characteristic peak is observed over the 3’ss of both constitutive and skipped 
exons (Figure 7 and Figure 8, bottom panels). By contrast, in cells overexpressing 
hnRNPA1, U2AF2 crosslinking density near alternative exons shifts downstream 
of the 3’ss and the peak is substantially reduced (Figure 8 bottom panel, red line).  
 
To determine if there is a direct relationship between hnRNPA1 binding and 
changes in U2AF2 or SRSF1 association with transcripts, we examined regions 
flanking the 3’ss of skipped exons with hnRNPA1 crosslinking in either conditions 
(Figure 9). In regions with no detectable hnRNPA1 crosslinks, the change in 
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U2AF2 crosslinking exhibits a bimodal distribution, which corresponds to regions 
flanking the 3’ss that show either increased or decreased U2AF2 crosslinking in 
hnRNPA1 overexpression cells relative to control cells (Figure 9 top panel, blue). 
By contrast, U2AF2 crosslinking to the vicinity of the 3'ss is significantly reduced 
when direct association of hnRNPA1 is also evident (Figure 9 top panel, pink). 
Changes in SRSF1 crosslinking appears to be independent of direct hnRNPA1-
RNA interactions (Figure 9 bottom panel). To determine if changes in U2AF2 
crosslinking correlated with hnRNPA1-dependent splicing regulation we 
sequenced polyA+ selected RNA libraries from control and hnRNPA1 
overexpression cells (Table 5). Of the 267 hnRNPA1-regulated cassette exons, 
the majority exhibited increased levels of exon skipping upon hnRNPA1 
overexpression (Figure 10). A total of 44 hnRNPA1-regulated splicing events also 
exhibited changes <2-fold change in U2AF2 intronic crosslinking (Table 6). 54% of 
hnRNPA1-dependent exon skipping events also exhibit depletion of U2AF2 
crosslinking within 200bp of the 3’ss, whereas 46% show hnRNPA1-dependent 
increases in U2AF2 crosslinking in the same region. For example, hnRNPA1-
dependent U2AF2 redistribution and alternative splicing COG4 (Conserved 
oligomeric Golgi complex subunit 4; Figure 11) and SRSF6 (serine/arginine-rich 
splicing factor 6 or SRp55; Figure 12). In both cases, U2AF2 crosslinking near the 
3’ splice sites is reduced in the cell lines over expressing hnRNPA1 (Figure 11 and 
Figure 12). 
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Figure 7 Crosslinking near 3’ splice sites of constitutive exons. Normalized 
crosslinking distribution for hnRNPA1 (left panel), SRSF1 (right panel) and U2AF2 
(bottom panel) in wild type (blue line) and hnRNPA1 overexpression cell lines (red 
line) with 95% confidence interval (grey area). 
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Figure 8 Crosslinking near 3’ splice sites of cassette exons. Normalized 
crosslinking distribution for hnRNPA1 (left panel), SRSF1 (right panel) and U2AF2 
(bottom panel) in wild type (blue line) and hnRNPA1 overexpression cell lines (red 
line) with 95% confidence interval (grey area).  
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Figure 9 hnRNPA1 induced redistribution of U2AF2 crosslinking near 3’ splice 
sites. Nature log fold change distribution of U2AF and SRSF1 within 200bp intron 
regions near 3’ splice sites of cassette exons. Blue bars corresponds to annotated 
alternative splicing events with no evidence of hnRNPA1 crosslinking in either 
condition and pink represents annotated events with detectable hnRNPA1 
crosslinking. 
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Figure 10 Bar graph depicting the number of alternative cassette exons 
differentially expressed upon hnRNPA1 overexpression.  
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Figure 11 Example of hnRNPA1-dependent modulation of U2AF2 crosslinking 
and alternative splicing on COG4. UCSC genome browser example of COG4   and 
CLIP read coverage data for U2AF2 under control and hnRNPA1 overexpression. 
The sashimi plot representing MISO analysis of RNA sequencing data from 
samples used for iCLIP. It represents splicing data corresponding to the exon show 
in the USCS genome browser snapshots. 
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Figure 12 Example of hnRNPA1-dependent modulation of U2AF2 crosslinking 
and alternative splicing on SRSF6. UCSC genome browser example of SRSF6   
and CLIP read coverage data for U2AF2 under control and hnRNPA1 
overexpression. The sashimi plot representing MISO analysis of RNA sequencing 
data from samples used for iCLIP. It represents splicing data corresponding to the 
exon show in the USCS genome browser snapshots. 
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Table 5 mRNA-seq mapping statistics from hnRNPA1 over expressing or control 
cells.  
 
hnRNPA1 
OE1 
hnRNPA1 
OE2 
hnRNPA1 
CTL1 
hnRNPA1 
CTL2 
Total count 17.48M 20.98M 20.06M 17.35M 
Mapped 
count 1.96M 15.07M 13.84M 12.56M 
Mapped 
percentage 11.20% 71.80% 69.00% 72.40% 
Unique 
count 1.57M 14.62M 13.49M 12.27M 
Unique 
percentage 80.00% 97.00% 97.50% 97.70% 
Junction 
count 0.39M 5.35M 5.82M 5.31M 
Junction 
percentage 24.80% 36.60% 43.10% 43.30% 
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Table 6 summary hnRNPA1-dependent changes in exon skipping and U2AF2 
positioning.  
    
hnRNPA1-dependent change in 
U2AF2 crosslinking near 3'ss   
  
Total # of 
Events 
Increased 
U2AF2 
Decreased 
U2AF2 
Redistirbution 
to Alu 
hnRNPA1-
dependent exon 
inclusion 
3 2 1 2 
hnRNPA1-
depednent exon 
skipping 
41 19 22 17 
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3.3.3 Overexpression of hnRNPA1 Triggers U2AF2 Re-localization to Alu 
Elements 
Previous work by Zarnack et al. demonstrated that hnRNP proteins, such as 
hnRNPC, can antagonize binding of U2AF2 to Alu element, to repress their 
exonization [10]. We asked if hnRNPA1 similarly repressed U2AF2 crosslinking to 
Alu elements by measuring global distribution of crosslinks for each protein 
overlapping of antisense Alu elements throughout intronic regions with titration of 
hnRNPA1 levels. Surprisingly upon overexpression of hnRNPA1, we detected a 
dramatic increase in U2AF2 crosslinking to antisense Alu-containing RNA 
transcripts compared to control cells (Figure 13). Conversely, hnRNPA1 
crosslinking globally decreases over Alu elements with overexpression. By 
contrast to U2AF2, crosslinking of SRSF1 to antisense Alu elements shows no 
appreciable changes, suggesting that the effect of hnRNPA1 is specific to U2AF2.  
 
These results suggest that Alu elements with increased U2AF2 crosslinking are 
located in cis- relative to skipped exons (Alu elements upstream or downstream of 
a splicing event) (Figure 14).  To test this hypothesis we compared the proportion 
of U2AF2 crosslinks within Alu-elements relative to flanking sequences across 
individual exon skipping events in control or hnRNPA1 overexpression cells. The 
scatter plot shown in Figure 15, demonstrates that the proportion of U2AF2 
crosslinks present in Alu elements increases significantly across virtually all exon 
skipping events, upon hnRNPA1 overexpression, whereas the proportion of 
hnRNPA1 crosslinks are decreased (Figure 15). By contrast, the proportion of 
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SRSF1 crosslinks to Alu elements are refractory to changes in hnRNPA1 
expression levels (Figure 15). These data demonstrate a global change in U2AF2-
Alu association and refute the hypothesis that a few spurious Alu-elements are 
responsible for the signal observed in Figure 13. We found that 41% of hnRNPA1-
dependent exon skipping events exhibited redistribution of U2AF2 to adjacent Alu 
elements (Table 6).  An example from the PIEZO1 gene is shown in Figure 
16. Taken together, these data demonstrate that overexpression of hnRNPA1 
triggers U2AF2 relocalization to Alu elements.  
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Figure 13 Aggregated read counts on Alu elements and nearby regions.  
Aggregated read counts on Alu elements and nearby regions for U2AF2 (left 
panel), hnRNPA1 (right panel) and SRSF1 (bottom panel). Blue represents wild-
type binding of the given RNA binding protein and red represents hnRNPA1 
overexpression of the log10 number of iCLIP read counts across all antisense-Alu 
elements. 
60 
 
 
  
Figure 14 Potential regulatory mechanisms of Alu element.  Model representing 
two potential modes by which U2AF2 may associate with Alu RNA: trans- 
competition suggests U2AF2 binds to Alu elements on other RNAs, while a cis-
competition suggest U2AF2 binds to Alu elements within the same RNAs that a 
particular exon is associated. 
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Figure 15 hnRNPA1 overexpression correlates with global redistribution of U2AF2 
signal to Alu RNA elements. Scatter plot of all human cassette exons measuring 
the proportion of U2AF2 iCLIP crosslinks found within Alu elements within the 
cassette exon event over the total number of crosslinks found within the event. 
Proportions from control and hnRNPA1 overexpression samples are compared for 
each individual cassette exon event. 
62 
 
 
  
Figure 16 Example of hnRNPA1-dependent modulation of U2AF2-Alu interaction 
on PIEZO1. UCSC genome browser snapshot depicting U2AF2 redistribution to 
anti-sense Alu elements in PIEZO1. iCLIP data (read coverage) for U2AF2 in 
control and hnRNPA1 overexpression cell lines. Sashimi plot representing MISO 
analysis of RNA sequencing data from samples used for iCLIP. This plot for 
PIEZO1 represents splicing data corresponding to the exon show in the USCS 
genome browser snapshots. 
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3.3.4 Alu Elements May Function as Cis-regulatory Elements that Compete 
with Authentic Exons for Binding to Splicing Factors 
Alu elements influence alternative splicing, although the mechanisms are poorly 
understood [7, 144, 157-159]. We investigated the positions of Alu-elements with 
hnRNPA1-dependent changes in U2AF2 crosslinking relative to the 3’ splice site 
of constitutive or skipped exons. As expected, we observed that Alu elements are 
closer to skipped than constitutive exons (p < 1.4e-47, Wilcoxon rank-sum test, 
Figure 17, compare green and yellow boxes). But yet, those Alu elements with 
hnRNPA1-dependent increases in U2AF crosslinking are significantly closer to 
exons than those that are unchanged (p < 9.5e-93, Figure 17). Taken together our 
data suggest the intriguing hypothesis that Alu-elements may function as cis-
regulatory elements that compete with authentic exons for binding to splicing 
factors. 
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Figure 17 Distance of Alu elements to the closest exons. Box plot representing the 
distance of Alu elements from cassette exons (blue) and constitutive exons 
(orange) that show no change in U2AF2 cross-linking versus those that show an 
increase in U2AF2 crosslinking. 
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3.4 Discussion 
Alu elements influence gene expression in diverse ways [144, 160-164]. The 
results presented here implicate Alu elements in splicing regulation.  The proximity 
of hnRNPA1-responsive Alu-U2AF2 interaction sites to exons supports this 
hypothesis. Recently, Zarnack et al. demonstrated that hnRNPC competes with 
U2AF2 to repress inclusion of Alu-derived exons in mRNA [10]. We find that 
hnRNPA1 overexpression correlates with increased U2AF2 association with Alu-
derived RNA sequences. This occurs with no change in hnRNPC protein 
expression or localization. We hypothesize that Alu elements function as a sink for 
U2AF2. In this model, U2AF2 dissociation from Alu-derived sequences maybe 
prevented by hnRNPA1. Alternatively, hnRNPA1 may alter U2AF2 RNA binding 
specificity thereby enhancing association with Alu elements. Taken together, our 
data demonstrate that Alu-derived sequences function as RNA regulatory 
elements that respond to changes to the intracellular concentration of splicing 
factors.  Our data are also consistent with recent U2AF2 CLIP-seq results which 
identified a strong correlation between exon skipping and atypical intronic binding 
sites upstream of exons or within exons [89]. As a primate-specific 
retrotransponson elements, Alu may speed up human evolution by weakening the 
splice sites of certain constitutive exons. Such changes may enable them to be 
excluded from the final transcript, and therefore increased diversity of human 
proteome. Our results suggest the intriguing hypothesis that retrotransposons 
contribute to species-specific differences in alternative splicing throughout the 
primate lineage (Figure 18).  
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Figure 18 Schematic describing a role for Alu-elements in the evolution of primate-
specific alternative splicing.  
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 regSNP-intron: A Tool for Prioritizing Intronic Single Nucleotide 
Substitution 
4.1 Introduction 
Human genome carries a large number of single nucleotide variants (SNVs) and 
many SNVs are believed to be involved in disease. While most studies focus on 
SNVs that locate in exonic regions, more and more studies suggest that intronic 
SNVs (iSNVs) may cause disease by affecting splicing regulation [12, 33, 36, 165]. 
Intronic SNVs typically affect alternative splicing by disrupting the recognition of 
splicing sites. For example, studies show that 99.5% cases in familial 
dysautonomia (FD) have the intronic mutation near 5’-splice site of exon 20 in 
IKBKAP gene, which can cause the exon skipping of exon 20 and result in the 
malfunction of IKBKAP [36, 38, 39]. Other evidence suggests that iSNVs can 
perturb the RBP binding affinity of cis-regulatory elements [165-167]. Since there 
are a larger number of iSNVs, but only a small fraction of them can potentially 
cause altered biological functions, it is important to be able to prioritize these SNVs 
using computational approaches. The selected variants with higher pathogenic 
potentials can be further subjected to additional experimental validation. 
 
In order to effectively analyze the large number of iSNVs for further functional and 
clinical studies, efficient bioinformatics algorithms are needed for prioritizing iSNVs. 
One bioinformatics tool, SPANR (Splicing-based Analysis of Variants) [16], is 
designed for evaluating how individual SNVs impact splicing regulation, by 
predicting its maximum changes on the percentage of inclusion (dPSI) of the 
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nearby exons. It extracts over 1000 genomic features around SNVs and predict 
the potential splicing outcome by training a neural network with 16 tissues from 
human BodyMap 2.0 RNA-Seq data. This tool, however, is not designed for 
assessing whether the target iSNVs cause deleterious phenotypes since it does 
not further evaluating the level of the resultant splicing changes impacts the protein 
function. Another widely used tool, CADD (Combined Annotation Dependent 
Depletion), predicts pathogenic variants with support vector machine (SVM) by 
combining annotations from multiple sources including conservation scores such 
as PhyloP, regulatory information such as transcription factor binding, and protein-
level scores such as SIFT and PloyPhen [134]. Regarding to iSNVs, however, the 
available annotations are limited to genomic features such as conservation score 
and distance to splicing sites. Our earlier studies on small insertions/deletions 
(INDELs) [17, 18], alternatively spliced exons [168], and synonymous SNVs 
indicate that simply including or excluding a stretch of amino acid residues does 
not guarantee an alteration on the protein function. This is also consistent with 
numerous reports that splicing variations can be “passenger” events, and thus 
inconsequential to the organismal phenotype [20]. Therefore, in order to fully 
appreciate the molecular implications of functional iSNVs, it is critical to integrate 
the protein structure-related features that determine the effects of alternatively 
spliced exons on protein structure and function. 
 
In this study, we combined the information of both the impact of iSNVs on splicing 
regulation and the protein structural features of potentially altered exons. We 
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extracted pathogenic iSNVs from Human Gene Mutation Database (HGMD) and 
carefully selected a subset of iSNVs from 1000 Genome project as neutral SNVs 
[169, 170]. A random forest classifier [171] was built to prioritize the disease-
causing probability of iSNVs. The classifier was also tested on the independent 
dataset from ClinVar database. The result suggests that our method can predict 
the disease-causing probability of iSNVs with high accuracy by combining the 
genomic features and structural features around iSNVs. As the price of whole-
genome sequencing drops below 1000 dollars, there are more and more iSNV 
data available. Our study can help to prioritize and screen the potential pathogenic 
iSNVs for further experimental analysis and better understand the role of iSNVs in 
diseases. The tool is available at 
http://clark.compbio.iupui.edu/regsnp_intron_web. The pre-computed prediction 
result for all the possible iSNVs in human genome is also integrated in the 
ANNOVAR tool [172]. 
 
4.2 Materials and Methods 
4.2.1 Data Set 
To prioritize the pathogenic probability of iSNVs, we construct our training dataset 
by combining the known pathogenic SNVs from HGMD and neutral SNVs from 
1000 genome project (Figure 19, Figure 20). For pathogenic iSNVs in HGMD, we 
only include the ones that labeled as “DM” (disease causing). Those are the 
variants that are manually curated to cause disease phenotypes through aberrant 
mRNA splicing. Neutral iSNVs were selected from the variants documented in the 
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1000 genomes dataset, which were derived from the genomic sequencing data of 
2,500 individuals without apparent clinical phenotype. In order to minimize false 
negative records in our training dataset, we only select those iSNVs with a minor 
allele frequency (MAF) greater than 10%. This selection scheme results in 2,438 
and 2,104,613 deleterious and neutral SNVs, respectively.  
 
We further divided all selected iSNVs into two categories, the ones that are close 
to the splicing junction sites, or on splicing sites (on_ss), and the ones that are 
more distal into the intronic regions (off_ss). These variants are further separated 
since the variants in these regions may impact splicing outcome through different 
molecular mechanisms. Specifically, the variants close to the splicing junction sites 
(on_ss) may directly interfere with the splicesome formation, while the ones further 
away from the junction sites (off_ss) may impact the splicing regulation by affecting 
the binding of regulatory RNA binding proteins. Splicing sites are defined as 
upstream 3bp to downstream 7bp for donor sites and upstream 13bp to 
downstream 1bp for acceptor sites [173]. In total, 1,865 on_ss and 573 off_ss 
pathogenic iSNVs were extracted from the HGMD; 3,386 on_ss and 2,104,613 
off_ss neutral ones were derived from the 1000 genomes database. As shown in 
Figure S2, comparing to the neutral variants, pathogenic variants tend to be closer 
to the splicing junction sites. To avoid the potential biases led by the differences of 
the distances from junction sits, we randomly selected 852 off_ss iSNVs from the 
1000 genomes variants by matching the distance distribution of the HGMD variants. 
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This process ensured a more balanced training dataset with similar distance 
distribution between the pathogenic and neutral variants (Figure 21). 
 
For each of the on_ss and off_ss dataset, we randomly select 2/3 of the data as 
training set to build a random forest classifier (Figure 21). The remaining 1/3 are 
used as validation set. To further test the performance of our model, we extracted 
pathogenic and benign iSNVs from ClinVar database as independent testing set 
[21]. In order to ensure the quality of variant disease association in the ClinVar 
data set, we only keep the iSNVs with at least 2 submitters, with the exception of 
pathogenic off_ss iSNVs where we only require single submitter due to the limited 
number of iSNVs of this category in the ClinVar database. In total, we extracted 
121 on_ss and 51 off_ss pathogenic iSNVs, and 167 on_ss and 883 off_ss benign 
iSNVs from ClinVar. 
 
In order to select the features that best distinguish the differences between 
pathogenic and neutral iSNVs, we classified all the features into three categories, 
genomic features characterizing how individual iSNVs affect splicing regulation, 
structural features evaluating how the inclusion/exclusion of alternatively spliced 
exons affect protein function, and evolution conservation. Most of these features 
show significant separation power between pathogenic and neutral iSNVs base on 
Wilcoxon rank-sum test (Figure 22, Table 7). 
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Figure 19 General workflow and feature sources. 
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Figure 20 Model training and testing process. SNVs from 1000 Genome project 
and HGMD are divided into on_ss and off_ss iSNVs. Each category is then split 
into 2/3 for training and the rest 1/3 for validation. SNVs from Clinvar database are 
used for independent testing. 
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Figure 21 Histogram of distance between off_ss iSNVs and the closest exons. 
iSNVs from 1000 genome project are farther away from exon boundaries 
comparing to the iSNVs from HGMD. A down-sampling is needed to correct such 
bias.  
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Figure 22 Volcano plot of all features. Each dot represents a feature in each of 
three categories: splicing (grey), conservation (blue), and structure (red). X-axis 
shows the difference of median value between pathogenic and neutral iSNVs. Y-
axis represents adjusted p-value of Wilcoxon rank-sum test between pathogenic 
and neutral iSNVs. 
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4.2.2 Splicing Features 
Junction strength of closest exon boundary is calculated for each iSNV based on 
the position weight matrices (PWMs) derived from canonical splicing sites [173]. 
The junction strength is measured by adding up information contents of positions 
-3 to +7 for donor sites and positions -13 to +1 for acceptor sites. Further, for on_ss 
iSNVs, the change of junction strength caused by allelic substitution is also 
computed. 
 
The impact of iSNVs on RBP binding affinity is measured based on the PWMs 
obtained from RBPDB and cisBP-RNA databases [24, 174]. A total of 201 PWMs 
are collected from those two databases. The magnitude and posterior probability 
of RBP binding change are measured using methods described in previous 
study[17]. The matching score is calculated as: 
𝑆𝑆 = �𝑠𝑠𝑖𝑖,𝑗𝑗𝑘𝑘
𝑖𝑖=1
 , 𝑗𝑗 ∈ {𝐴𝐴,𝐶𝐶,𝐺𝐺,𝑇𝑇} 
where k represents the width of RBP binding site, and si,j measures the logarithmic 
ratio between observed frequency and random background frequency: 
𝑠𝑠𝑖𝑖,𝑗𝑗 = 𝑙𝑙𝑙𝑙𝑙𝑙2 (𝑛𝑛𝑖𝑖,𝑗𝑗 + 𝑐𝑐𝑖𝑖,𝑗𝑗)/(𝑁𝑁 + ∑ 𝑐𝑐𝑖𝑖,𝑗𝑗𝑗𝑗∈{𝐴𝐴,𝐶𝐶,𝐺𝐺,𝑇𝑇} )𝑑𝑑𝑗𝑗  
Here, ni,j is the count of base j on position i in the PWM, ci,j is the pseudocount. N 
is the total number of binding sites used to derive the PWM. And dj is the prior base 
frequency of base j (dj = 0.25 for j = A, C, G, T). 
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The mean and variance of matching score distributions for binding and non-binding 
events are estimated as: 
𝑀𝑀𝑠𝑠 = � � 𝑓𝑓𝑖𝑖,𝑗𝑗 × 𝑠𝑠𝑖𝑖,𝑗𝑗
𝑗𝑗∈{𝐴𝐴,𝐶𝐶,𝐺𝐺,𝑇𝑇}
𝑘𝑘
𝑖𝑖=1
 
𝑉𝑉𝑠𝑠 = � � 𝑓𝑓𝑖𝑖,𝑗𝑗 × 𝑠𝑠𝑖𝑖,𝑗𝑗2 − (𝑓𝑓𝑖𝑖,𝑗𝑗 × 𝑠𝑠𝑖𝑖,𝑗𝑗)2
𝑗𝑗∈{𝐴𝐴,𝐶𝐶,𝐺𝐺,𝑇𝑇}
𝑘𝑘
𝑖𝑖=1
 
where fi,j is the approximation of the true frequency of base j at position i. For 
binding events, 
𝑓𝑓𝑖𝑖,𝑗𝑗 = 2𝑠𝑠𝑖𝑖,𝑗𝑗4  
and for non-binding events, fi,j = 0.25. 
 
The magnitude of an iSNV affecting the RBP binding is defined as the log-
likelihood ratio between alternative allele and reference allele: 
𝑀𝑀 = 𝑙𝑙𝑙𝑙𝑙𝑙2 𝑃𝑃(𝑆𝑆𝐴𝐴|𝐵𝐵)/𝑃𝑃(𝑆𝑆𝐴𝐴|𝑁𝑁𝐵𝐵)𝑃𝑃(𝑆𝑆𝑅𝑅|𝐵𝐵)/𝑃𝑃(𝑆𝑆𝑅𝑅|𝑁𝑁𝐵𝐵) = 𝑙𝑙𝑙𝑙𝑙𝑙2 ∫
1
�2𝜋𝜋𝑉𝑉𝑠𝑠 𝑒𝑒−12�𝑥𝑥−𝑀𝑀𝑠𝑠𝑉𝑉𝑠𝑠 �2𝑑𝑑(𝑥𝑥)𝑆𝑆𝐴𝐴−∞
∫
1
�2𝜋𝜋𝑉𝑉𝑠𝑠 𝑒𝑒−12�𝑥𝑥−𝑀𝑀𝑠𝑠𝑉𝑉𝑠𝑠 �2𝑑𝑑(𝑥𝑥)𝑆𝑆𝑅𝑅−∞  
Where SR and SA represent the matching score of sequence with reference allele 
and alternative allele. P(SA|B) and P(SR|B) denotes the probability of the given 
sequence being a binding site ,while P(SA|NB)  and P(SR|NB) denotes the 
probability of being non-binding site. 
 
A Bayesian-based posterior probability of RBP binding change is calculated as: 
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𝑃𝑃 = 𝑃𝑃(𝑅𝑅 = 𝐵𝐵,𝐴𝐴 = 𝑁𝑁𝐵𝐵|𝑆𝑆𝑅𝑅 ,𝑆𝑆𝐴𝐴) + 𝑃𝑃(𝑅𝑅 = 𝑁𝑁𝐵𝐵,𝐴𝐴 = 𝐵𝐵|𝑆𝑆𝑅𝑅 ,𝑆𝑆𝐴𝐴)
= � 𝑃𝑃(𝐵𝐵)�1 − 𝑃𝑃(𝐵𝐵)��𝑃𝑃(𝑆𝑆𝑅𝑅|𝑅𝑅 = 𝐵𝐵)𝑃𝑃(𝑆𝑆𝐴𝐴|𝐴𝐴 = 𝑁𝑁𝐵𝐵) + 𝑃𝑃(𝑆𝑆𝑅𝑅|𝑅𝑅 = 𝑁𝑁𝐵𝐵)𝑃𝑃(𝑆𝑆𝐴𝐴|𝐴𝐴 = 𝐵𝐵)�
𝑃𝑃(𝑆𝑆𝑅𝑅)𝑃𝑃(𝑆𝑆𝐴𝐴) 𝑑𝑑(𝐵𝐵)10  
 
4.2.3 Evolutionary Features 
Basewise conservation scores (PhyloP) of 99 vertebrate genomes with Human 
were downloaded from UCSC Genome Browser [175]. The scores on iSNVs loci 
as well as the average scores of +/-3bp and +/-7bp regions around the iSNVs were 
extracted and used in the machine learning model. 
 
4.2.4 Protein Structure Features 
Protein structural features of closest exons of iSNVs were evaluated. The protein 
disorder score, protein secondary structure and solvent accessible surface area 
(ASA) were precomputed for all the known protein-coding genes using SPINE-D 
and SPINE-X [25, 176]. The known protein domains were extracted from Pfam 
database [177]. The percentage of closest exon region overlaps with Pfam 
domains were measured. The post-translational modification sites (PTMs) were 
extracted from dbPTM 3.0 database [178]. The number of PTM sites per 100 
amino acids on the closest exon were calculated. 
 
4.2.5 Machine Learning Model 
Two different random forest classifiers were built for on_ss and off_ss iSNVs 
respectively. Since random forest performs an implicit feature selection, only the 
important features will be selected to build each tree in the forest. The grid search 
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with 3-fold cross validation was used to fine-tune the hyperparameters such as 
number of trees and max depth. For on_ss iSNVs, 52 trees with depth equals to 
13 were built. For off_ss iSNVs, the random forest contains 59 trees with depth 
equals to 20. 
 
4.2.6 Allele Frequency of SNVs in GTEx 
SNVs and corresponding allele frequencies were obtained from GTEx analysis v6 
whole-genome sequencing data. We extracted iSNVs within 300bp of exon 
boundaries for prediction. 17,194 on_ss iSNVs and 630,557 off_ss iSNVs are left 
for further analysis.   
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4.3 Results 
4.3.1 Pathogenic iSNVs Tend to Affect Alternative Splicing 
Two sets of features were used to evaluate the impacts of individual iSNVs on 
splicing regulation: a) splicing junction score that quantifies splicing strength and 
b) how iSNVs to be predicted to affect the binding affinities of RNA-binding proteins 
(RBPs). Junction score is computed by position weighted matrices (PWMs) that 
measuring sequence features around canonical splicing sites. (Methods). The 
higher the score is, the more likely the corresponding exon is included in the final 
transcribed product. Our result shows that, while junction score change caused by 
neutral on_ss iSNVs can either increase or decrease (Figure 23), pathogenic 
on_ss iSNVs tend to decrease the junction strength of both donor and acceptor 
splicing sites. The median junction score change of pathogenic iSNVs (-2.96 for 
donor sites; -2.23 for acceptor sites) is significantly larger than the median score 
change of neutral ones (0.034 for donor sites; -0.059 for acceptor sites) (adjusted 
Wilcoxon rank-sum test p-value = 1.63*10-211 and 1.28*10-143 for donor site and 
acceptor site separately) (Table 7, Figure 23). This suggests that pathogenic 
iSNVs have a tendency to disrupt protein function by causing exon skipping. 
 
To evaluate the impacts of iSNVs on RBP binding, we computed both the 
magnitude and the probability of matching score changes caused by iSNVs for 201 
RBPs with known position weight matrices (PWMs, Methods). We show that 
pathogenic and neutral iSNVs showed significant differences in impacting the 
binding of many RBPs.  
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Among those 201 RBPs, a large proportion of them have significant separation 
power between pathogenic and neutral iSNVs (137 and 43 RBPs with adjusted 
Wilcoxon rank-sum test p-value < 0.05 for on_ss and off_ss iSNVs separately) 
(Figure 22). 
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Figure 23 Distribution of junction score change caused by in pathogenic (red) and 
neutral (black) on_ss iSNVs. Top and bottom panels represent donor sites and 
acceptor sites separately. 
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Table 7 Wilcoxon rank-sum test of all features. Delta median is the difference 
between median values of neutral and pathogenic iSNVs. 
  on_ss iSNV off_ss iSNV 
Feature 
Delta 
median P-value 
Delta 
median P-value 
Min disorder score 0.025 
2.27E-
008 0.033 
1.77E-
004 
Max disorder score 0.156 
7.30E-
017 0.059 
1.70E-
002 
Mean disorder score 0.186 
8.89E-
012 0.083 
2.20E-
002 
Mean disorder structure 
region 0.003 
9.76E-
001 -0.041 
3.00E-
001 
Mean disorder disorder 
region 0.087 
6.60E-
016 0.023 
7.64E-
003 
Switch number 0.000 
2.07E-
003 0.000 
6.26E-
001 
Min disorder length 0.064 
8.78E-
011 0.024 
6.83E-
002 
Max disorder length 0.064 
6.69E-
012 0.062 
6.00E-
002 
Mean disorder length 0.106 
2.18E-
011 0.047 
5.04E-
002 
Min structure length -0.127 
4.31E-
004 -0.044 
1.27E-
002 
Max structure length -0.038 
3.27E-
003 -0.128 
4.25E-
003 
Mean structure length -0.086 
9.62E-
004 -0.134 
6.79E-
003 
Min secondary structure 
score 0.015 
5.46E-
001 0.071 
1.75E-
002 
Max secondary structure 
score -0.050 
1.06E-
001 0.135 
1.38E-
001 
Mean secondary structure 
score -0.025 
5.56E-
001 0.202 
2.22E-
003 
Min alpha 0.046 
3.63E-
003 0.089 
2.11E-
004 
Max alpha -0.004 
8.37E-
001 0.012 
2.40E-
002 
Mean alpha -0.051 
2.18E-
001 0.112 
9.54E-
003 
Min beta 0.006 
8.18E-
001 -0.014 
2.03E-
001 
Max beta -0.257 
1.61E-
003 -0.677 
4.59E-
003 
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Mean beta -0.077 
1.30E-
002 -0.239 
3.30E-
003 
Min coil 0.004 
1.64E-
001 -0.022 
7.54E-
002 
Max coil -0.006 
1.35E-
002 -0.022 
2.59E-
003 
Mean coil 0.094 
6.18E-
001 -0.097 
2.47E-
002 
Min ASA 0.054 
3.54E-
007 0.057 
1.54E-
002 
Max ASA 0.113 
4.31E-
004 0.038 
7.02E-
001 
Mean ASA 0.216 
1.15E-
013 0.165 
4.72E-
003 
PTM 0.000 
6.62E-
001 0.000 
5.76E-
003 
PFAM -0.850 
6.28E-
017 -0.699 
3.23E-
006 
Acceptor strength 0.187 
1.40E-
007 0.136 
1.96E-
004 
Donor strength 0.209 
1.79E-
002 0.171 
6.68E-
003 
Acceptor strength change 0.746 
4.08E-
145 NA NA 
Donor strength change 1.000 
1.49E-
213 NA NA 
PhyloP 1bp -0.854 
0.00E+0
00 -0.362 
7.35E-
041 
PhyloP 3bp -1.000 
0.00E+0
00 -0.290 
3.76E-
025 
PhyloP 7bp -1.000 
1.51E-
284 -0.356 
9.39E-
028 
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4.3.2 Pathogenic iSNVs Happen at Conserved Regions 
Previous studies show that evolutionary conservation can be an important feature 
in predicting the disease-causing probability of SNVs [131, 179]. Our analysis 
confirm this observation. We calculate the PhyloP 100-way conservation score on 
the locus of iSNV itself, 3bp region and 7bp upstream and downstream the iSNV.  
Our result show that the pathogenic iSNVs locate at the loci with significantly 
higher conservation scores than the neutral ones do (Figure 24). For on_ss iSNVs, 
the median conservation score of pathogenic iSNV loci (3.08) is 3.11 higher than 
the median score of neutral ones (-0.03) with adjusted Wilcoxon rank-sum test p-
value < 1.00 * 10-300. The large positive PhyloP scores on pathogenic iSNV loci 
suggest those loci evolve much slower than expected. For off_ss iSNVs, the 
median conservation score of pathogenic iSNV loci (0.31) is 0.59 higher than the 
median score of neutral ones (-0.28) with adjusted p-value = 3.21 * 10-38. This 
indicates that the iSNVs happen at more conserved loci are more likely to be 
disease-causing.  
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Figure 24 Q-q plot of PhyloP score between pathogenic and neutral iSNVs. 
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4.3.3 Pathogenic iSNVs Tend to Locate Close to Exons of Functional 
Important Regions 
To further evaluate the impact of iSNVs on protein function, we calculate the 
structural features that characterize the functions of potentially alternatively spliced 
exons. We hypothesize that pathogenic iSNVs tend to disrupt the splicing of the 
exons in key protein structural regions. We capture the protein structural features 
of the closest exons of iSNVs such as the probability of being intrinsically 
disordered, secondary structure (probability of being alpha helix, beta sheet or 
random coil) and soluable accessible surface areas (ASA) (Table 7). We also 
calculate the percentage of affected exon region that overlaps with known protein 
domains and contains post-translational modification sites. (Table 7) 
 
Our result suggests that, comparing to neutral iSNVs, exons that affected by 
pathogenic iSNVs have lower average disorder score and contain longer 
structured region (adjusted Wilcoxon rank-sum test p-value 2.03 * 10-11 and 4.97 * 
10-2 for on_ss and off_ss iSNVs respectively) (Table 7, Figure 25). It indicates that 
pathogenic iSNVs have higher probability of locating close to the exons within 
structured regions. In addition, exons close to pathogenic iSNVs have significantly 
smaller average ASA score (adjusted p-value 2.90 * 10-13 and 1.03 * 10-2 for on_ss 
and off_ss iSNVs respectively), which indicates that they are more likely to be 
located in the core protein regions as opposed to the surface of the protein 
molecule. Moreover, the closest exons of pathogenic iSNVs tend to have higher 
percentage of residues overlaping with known protein family domains (adjusted p-
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value 1.91 * 10-16 and 1.98 * 10-5 for on_ss and off_ss iSNVs respectively). All 
those results suggest that the exons affected by pathogenic iSNVs have a higher 
chance to reside in the functionally important protein regions. Therefore, including 
protein structural features can provide us additional information to predict the 
disease-causing probability of iSNVs. 
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Figure 25 Empirical cumulative distribution of structural features. Red lines 
represent pathogenic iSNVs. Black lines represent neutral iSNVs. Top panel 
shows mean disorder score. Middle panel shows mean accessible surface ares 
(ASA). Bottom shows percentage of exon length overlap with PFam. 
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4.3.4 Prioritizing iSNVs Based on Their Impact of Splicing Regulation and 
Protein Structure 
As stated above, since on_ss and off_ss iSNVs may affect splicing through 
different molecular mechanisms. While on_ss iSNVs may inhibit the assembly of 
spliceosome by decreasing the junction strength directly, off_ss iSNVs may affect 
the splicing by disrupting the RBPs binding to cis-regulatory elements. Therefore, 
we built two separate random forest classifiers for on_ss and off_ss iSNVs 
separately. The models are built on training set (2/3 of original dataset) and 
validated on validation set (1/3 of original dataset). Hyperparameters such as 
number of trees and maximum depth are grid searched by 3-fold cross-validation 
on training set. For on_ss iSNVs, 52 trees with maximum depth 13 are built. For 
off_ss iSNVs, the random forest contains 59 trees with maximum depth of 20. 
 
Based on the validation dataset (1/3 of the original dataset) that was not used in 
model training, our algorithm reaches AUROC 0.96 and Matthews correlation 
coefficient (MCC) 0.79 for on_ss iSNVs. This significantly outperformed SPANR 
with AUROC 0.77 and CADD with AUROC 0.81. For off_ss iSNVs, the AUROC is 
0.84 with MCC 0.52. As a contrast, the AUROC for SPANR and CADD are 0.54 
and 0.69 separately (Figure 26). Since SPANR focuses on evaluating the impact 
of variants on splicing regulation and CADD mainly uses genomic features such 
as conservation scores and distance to splicing sites for intronic variants, our 
results suggest that inclusion of the protein structure features of the affected exon 
significantly increases the model performance. 
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To further evaluate the prediction power of features related to splicing, 
conservation and structure features, we built separate models based on each of 
the three categories of features. For on_ss iSNVs, the AUROCs for splicing, 
conservation, and structure features are 0.92, 0.92, and 0.72 respectively (Figure 
27). For off_ss iSNVs, the AUROCs are 0.75, 0.68, and 0.63 for each category. 
These results demonstrate that each category of features provide important 
information in model prediction. The combination of all three types of features can 
help us reach the highest prediction performance. 
 
To control the false positive rate (FPR) of the prediction results, we report the 
iSNVs with FPR < 0.05 as “Damaging”, iSNVs with 0.05 <= FPR < 0.1 as “Possibly 
Damaging” and iSNVs with FPR >= 0.1 as “Benign”. As shown in Figure 3, the 
reported “Damaging” category (FPR<=0.05) can reach true positive rate (TPR) of 
0.85 and 0.45 for on_ss and off_ss iSNVs, respectively (Figure 26), while the 
sensitivity for the “Possibly Damaging” category is 0.90 and 0.52 for on_ss and 
off_ss iSNVs. 
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Figure 26 ROC curves on validation set. Top panel shows the comparison of ROC 
among regSNP-intron, SPANR, and CADD. Bottom panel shows the 
corresponding probability cutoffs and TPR when FPR = 0.05 (red) and FPR = 0.1 
(blue). 
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Figure 27 ROC curves of models built on three categories of features separately.  
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4.3.5 Evaluating Model Performance on Independent Testing Set 
We further evaluated our prediction performance with an independent test data set 
from ClinVar database. We collected 121 on_ss and 51 off_ss pathogenic iSNVs, 
and 167 on_ss and 883 off_ss benign iSNVs with at least two submitters from 
ClinVar as our independent testing set. All the ClinVar iSNVs which are also 
observed in HGMD and 1000 Genome projects were excluded from the training 
set during the training stage to avoid overfitting. Consistent with the results on 
validation set, our model also shows a better performance comparing with splicing 
effect predictor (SPANR) on the test set (Figure 28). The AUROC of regSNPs-
intron are 0.96 and 0.95 for on_ss iSNVs and off_ss iSNVs, while the AUROC of 
SPANR are 0.89 and 0.72 for on_ss iSNVs and off_ss iSNVs separately. These 
results suggest that our model has stable performance with high prediction 
accuracy over different data set. 
 
It is interesting to see the performance of both our method and SPANR are 
improved on the independent test set comparing to validation set. The potential 
reason might be that there are greater differences on specific features, such as 
evolution conservation, that are more likely to drive the separation between the 
pathogenic and benign iSNVs (Figure 29). Such features are likely to be one of the 
criteria that are used by the ClinVar data contributors. Despite of this potential bias, 
the ClinVar dataset can still serve as an independent test set to compare the 
relative performance among prediction algorithms, even though we think the 
absolute measurement of AUROC on ClinVar data set might be overly optimistic.  
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Figure 28 ROC curves on independent Clinvar testing set. 
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Figure 29 Distribution of PyhloP scores on training and testing set. PhyloP scores 
are more separable between pathogenic and benign iSNVs in Clinvar database 
(bottom) comparing with the ones in HGMD and 1000 genome (top). 
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4.3.6 Allele Frequency is Reversely Correlated with Disease-causing 
Probability 
In general, the allele frequency in the population should reflect the importance of 
allele’s biological function [180-184]. We hypothesize that the disease-causing 
probability of iSNVs obtained from Genotype-Tissue Expression Project (GTEx) 
using our model. GTEx project contains high quality genotyping information of 449 
healthy individual. Here GTEx data is used independent of 1000 Genome project 
to avoid overfitting. The iSNVs are divided into 20 bins based on their allele 
frequency. And the average disease-causing probabilities are calculated for each 
bin. As expected, we observed a strong negative correlation between allele 
frequency and disease-causing probability for both on_ss iSNVs (R2 = 0.47) and 
off_ss iSNVs (R2 = 0.90) (Figure 30). This observation suggests that the prediction 
of our model is consistent with previous studies which concluded that variants with 
high disease-causing probability are less likely to happen in the population [18]. 
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Figure 30 Correlation between average predicted disease-causing probability and 
average allele frequency in GTEx whole-genome sequencing data.  
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4.3.7 Pathogenic iSNVs Tends to Happen Near Exons which Can Tolerate 
Less iSNVs 
We further evaluated the prediction results of our model by investing the functional 
importance of nearby exons which are potentially affected by iSNVs. We 
hypothesize that functionally important exons can tolerate less iSNVs nearby, and 
therefore iSNVs are more likely to be predicted as pathogenic if they locate near 
functionally important exons. To test this hypothesis, we extracted 160,230 exons 
which have at least one iSNV within ±300bp of intronic regions based on GTEx 
whole-genome sequencing data. One iSNV is randomly selected per exon and the 
disease-causing probabilities are predicted using our model. Based on our 
hypothesis, iSNVs should have higher disease-causing probability if the affected 
exons have less iSNVs nearby, and vise versa. Our result confirmed this negative 
correlation between average disease-causing probability and the number of iSNVs 
around exons (R2 = 0.61, p-value = 0.007) (Figure 31). This indicates that 
pathogenic iSNVs tend to happen near functionally important exons.  
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Figure 31 Correlation between average predicted disease-causing probability and 
the number of iSNVs around exons. Pathogenic iSNVs tend to locate near exons 
which can tolerate less iSNVs. 
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4.4 Discussion 
Human genetic variants are known to be associated with many diseases. While 
next-generation sequencing technology enables exploring variants across the 
whole genome, many studies still focus on exonic regions. The main reason is that 
the variants locate outside the protein-coding regions are difficult to interpret and 
validate. However, introns, as the largest source of genetic variants in gene region, 
contain approximately a hundred times of more variants comparing to exons [185]. 
Cumulative evidence indicates that variants locating inside the intronic regions 
may have pathogenic effects through affecting splicing regulation. For instance, 
over 3,000 iSNVs in the Human Gene Mutation Database are documented to 
impact splicing, and further causes disease [169]. These iSNVs may affect splicing 
regulation through different mechanisms depending on the regions they locate in. 
Intronic SNVs that locate on the junction boundaries may have severe impacts on 
splicing by disrupting the recognition of splicing sites directly. For example, 
evidence shows that the donor site variant in intron 4 of adenomatous polyposis 
coli (APC) gene can lead to the initiation of colon cancer by causing the exon 
skipping of exon 4 [34, 51]. On the other hand, the iSNVs inside the intronic regions 
may have moderate effects which weaken the binding affinities of RNA-binding 
proteins that facilitate the splicesome formation. For instance, studies show that a 
G -> A substitution within an intronic splicing enhancer (ISE) downstream of exon 
3 in growth hormone gene (GH1) can cause familial isolated GH deficiency type II 
(IGHD II) by suppressing the binding of splicing factors [186-188]. Similarly, an 
intronic A -> T substitution 32bp downstream of BRCA1 exon 22 can inhibit the 
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splicing and result in the exon skipping in breast cancer [165, 189]. Due to the 
large number of intronic variants to be detected in the whole genome/exome 
sequencing projects and their complex regulatory mechanism in affecting splicing 
regulation, a computational approach is needed to prioritize the potential functional 
impacts of intronic variants detected by high-throughput assays. 
 
Although large-scale intronic variants are typically identified from the whole-
genome sequencing (WGS) experiment, a proportion of intronic variants, 
especially for the ones that are close to the splicing junctions, can be captured in 
the whole-exome sequencing (WES) experiments when they are locating in the 
flanking regions of the exon. Since the price of WES is relatively cheaper than 
WGS, many studies utilize WES to allow sequencing more samples. Hence, it is 
important to survey how many intronic variants can be identified through WES for 
further computational prediction and experimental validation. To evaluate this, we 
collected all the genetic variants from the exome aggregation consortium (ExAC). 
ExAC is an integrated data set which contains high-quality exome sequencing data 
of 60,706 unrelated individuals from a variety of large-scale sequencing projects 
such as NHLBI exome sequencing project (ESP) and 1000 genome project [190]. 
Among 7,908,659 SNVs documented in ExAC, over 50% of them (4,126,724) are 
locate within intronic regions. Excluding those iSNVs from downstream analysis 
would not only waste a large proportion of data generate from WES, but also limit 
the ability to identify functional important non-coding variants. Thus, the algorithm 
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we developed in this paper can server as a valuable component in the variant 
analysis of whole-exome sequencing projects.       
 
In this study, we evaluated the impact of genetic features and structural features 
on prioritizing pathogenic iSNVs. The disruption of variants on splicing regulation 
and the conservation of variants are already known to be powerful predictors of 
pathogenic SNVs in exon regions. In fact, such features have been used to 
evaluate impacts of synonymous variants in alternating splicing outcome [16], and 
whether they can lead to pathological phenotypes. In addition to these two types 
of features (impacts on splicing and evolution conservation), our previous study 
showed that the protein structural features can help us prioritize pathogenic micro-
insertions and deletions [18], as well as dys-regulated alternative splicing events 
[168]. Here, we demonstrated that integrating protein structural features can 
provide additional information in prioritizing the pathogenic effects of intronic 
variants, for both on- and off-splice site variants. This is consistent with our 
observation that pathogenic iSNVs tend to locate near exons within functionally 
important regions. As a result, by carefully categorizing iSNVs into two subtypes, 
we successfully build two models to prioritize disease-causing on_ss and off_ss 
iSNVs with low FPR and relative high TPR. Although tools like SPANR can be 
used to predict tissue-specific splicing changes induced by individual iSNVs, to our 
knowledge, there is no bioinformatics algorithm specifically designed for prioritizing 
pathogenic iSNVs. In conclusion, our method allows effectively prioritizing and 
screening pathogenic iSNVs generated by genome-wide scale genetic studies. 
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 Conclusions and Discussions 
5.1 Conclusions 
5.1.1 Conclusions on RBP Regulatory Network and Alu Emelemts 
As one of two key components of splicing regulation, trans-regulatory RBPs play 
critical roles in the regulatory machinery. However, among hundreds of splicing-
related RBPs, the majority of them are under-examined. In this project, we 
systematically investigated the interaction of three key splicing regulators: hnRNP 
A1, SRSF1, and U2AF in HEK293 cell line based on the high-throughput 
sequencing data generated by our collaborators. We observed that the 
overexpression of hnRNP A1 can trigger the transcriptome-wide redistribution of 
SRSF1 and U2AF. More specifically, the hnRNP A1 overexpression can inhibit the 
binding of SRSF1 and U2AF near 3’ splicing sites. This indicates that hnRNP A1 
can suppress the assembly of spliceosome by interrupting the SRSF1-mediated 
U2AF recruitment. In addition, we observed that the significant enrichment of U2AF 
in Alu-derived transcripts after hnRNP A1 overexpression. Our results show that 
Alu elements may act as cis-acting regulatory elements that compete with 
authentic exons for binding to U2AF. These results can help us understand the 
association among key RBPs in splicing regulatory machinery. The discovery on 
the function of Alu elements in splicing regulation can also provide meaningful 
information for understanding the role of Alus in primate evolution. 
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5.1.2 Conclusions on iSNV Prioritization 
Intronic variants are known to be related to many human diseases. However, due 
to the limitation of available data, there are few of algorithms developed to predict 
the disease-causing probability of intronic variants. As the increasing application 
of high-throughput sequencing technology, intronic variants start to attract more 
and more spotlights. In this study, we evaluated the impact of genetic features and 
structural features on prioritizing disease-causing iSNVs. The disruption of variants 
on splicing regulation and the conservation of variants are already known to be 
powerful predictors of pathogenic SNVs in exon regions. However, the alternation 
on pre-mRNA splicing does not necessarily mean the disruption on protein 
functions and phenotypes. Whether the potentially altered exon locates in key 
structural regions also plays a critical role on the functional impacts. Our previous 
study also shows that the protein structural features of alternatively spliced exons 
can increase the prediction power on pathogenic micro-insertions and deletions, 
as well as synonymous SNVs. Here, we demonstrated each category of features 
can be used to predict the disease-causing probability of iSNVs with a reasonably 
high accuracy. This suggests protein structural features can contribute an 
additional layer of information in predicting the disease-causing probability of 
iSNVs. By carefully categorizing iSNVs into different subtypes, we successfully 
built separate models to prioritize pathogenic on_ss and off_ss iSNVs with low 
false positive rate (FPR) and relative high true positive rate (TPR). With all the 
features combined, our model significantly outperform the widely used algorithm 
such as SPANR and CADD. As a result, our method allows effective prioritizing 
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and screening of pathogenic iSNVs generated by high-throughput platform such 
as whole-genome sequencing and SNP array. 
 
 
5.2 Future Directions 
5.2.1 Future Directions on RBP Regulatory Network 
To further understand the relationship between RBPs in splicing regulatory 
network, a machine learning approach can be used to study the relationship 
among different RNA binding proteins. The relationship among those proteins will 
be analyzed systematically based on different genomic context. It will help people 
to understand the function of those RNA binding proteins in alternative splicing 
regulation. The effects of each RNA binding proteins are combined together to 
predict the splicing outcome more precisely. 
 
After the comparison of iCLIP data of each RBP between control and hnRNP A1 
overexpressed cell line, a series of features such as peak changes near splicing 
sites will be collected. A Bayesian network will be built to interpret the relationship 
among different RNA binding proteins as well as predict the splicing outcome. 
Bayesian network is a probabilistic graphical model that represents a set of random 
variables and their conditional dependencies via a directed acyclic graph (DAG) 
[191]. Unlike other “black box” machine learning methods, Bayesian network can 
provide an interpretable model to help understand the splicing regulation. The 
binding status of hnRNP A1, SF2, U2AF as well as splicing change will be 
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considered as hidden variables. Those states will be inferred from observed 
evidence such as RBP motifs, iCLIP data and RNA-Seq. The joint probability of an 
exon can be calculated based on the network. The binding of hnRNP A1 and 
SRSF1 will be used to predict the U2AF binding. Their combination effects can be 
used to predict the splicing outcome. This method can not only predict the change 
of alternative splicing but also help understand how hnRNP A1 compete with 
SRSF1 to affect the binding of U2AF and further regulate the alternative splicing. 
 
The method used in this study can serve as a framework for other RNA binding 
protein analysis. With a similar study design, a computational model can be built 
on different RNA binding proteins to understand the splicing mechanism and 
predict the splicing outcome. The data and model generated from this study can 
also be integrated with the new data set to build more comprehensive models. An 
RNA binding protein network can be built. It will help people to understand the 
mechanism of splicing regulation. 
 
 
5.2.2 Future Directions on the Role of Alu Elements in Alternative Splicing 
Evolution 
Although our results suggest that Alu elements can recruit U2AF binding after 
hnRNP A1 over expression, the underlying mechanism still needs to be further 
investigated. The Alu family contains two major subfamilies: AluJ and AluS, as well 
as other small subfamilies [192].  They may play different roles in splicing 
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regulation. A machine learning approach can be applied to predict the impact of 
Alu elements insertion on alternative splicing outcome. Besides the sequence 
differences among different Alu subfamilies, various genomic features will be 
collected to help understand the cause of U2AF binding change on Alu elements. 
Those genomic features include: the distance to the closest exon, the splicing 
score of closest splice site, whether the closest exon is a skipped exon, etc. Also, 
the hnRNP A1 and SRSF1 binding changes on Alu elements will also be used to 
analyze the binding change of U2AF. The result will help us understand the 
function of Alu elements during splicing regulation, as well as the role of Alu in 
primate evolution. 
 
5.2.3 Future Directions on Functional Prediction of iSNVs 
Our long-term goal is to utilize the developed algorithm to screen candidate intronic 
variants for downstream functionally test on drug-induced cytotoxicity. Our 
collaborator has developed high-throughput assay which allows us to evaluate the 
impact of thousands of intronic variants on pre-mRNA splicing and drug cytotoxicity. 
With such ability, we can validate our prediction result in large-scale experiments. 
At the meantime, due to the size limitation of current pathogenic intronic variants 
database, more data is needed for training. The validation result from high-
throughput assay can provide additional information for us to refine the predictive 
model and achieve higher prediction power. 
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